<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Genet</journal-id><journal-id journal-id-type="pmc">plosgen</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Genetics</journal-title></journal-title-group><issn pub-type="ppub">1553-7390</issn><issn pub-type="epub">1553-7404</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">09-PLGE-RA-2235R2</article-id><article-id pub-id-type="doi">10.1371/journal.pgen.1001016</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Cancer Genetics</subject><subject>Genetics and Genomics/Complex Traits</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Public Health and Epidemiology/Epidemiology</subject></subj-group></article-categories><title-group><article-title>Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and <italic>TERT</italic>, a Cancer Susceptibility “Hot-Spot”</article-title><alt-title alt-title-type="running-head"><italic>TERT</italic> Variant Associated with Serous Ovarian Cancer</alt-title></title-group><contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Johnatty</surname><given-names>Sharon E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Beesley</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Xiaoqing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Macgregor</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Duffy</surname><given-names>David L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Spurdle</surname><given-names>Amanda B.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>deFazio</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gava</surname><given-names>Natalie</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Webb</surname><given-names>Penelope M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><collab xlink:type="simple">Australian Ovarian Cancer Study Group</collab><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><collab xlink:type="simple">Australian Cancer Study (Ovarian Cancer)</collab><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rossing</surname><given-names>Mary Anne</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Doherty</surname><given-names>Jennifer Anne</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Goodman</surname><given-names>Marc T.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lurie</surname><given-names>Galina</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Thompson</surname><given-names>Pamela J.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wilkens</surname><given-names>Lynne R.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ness</surname><given-names>Roberta B.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moysich</surname><given-names>Kirsten B.</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chang-Claude</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang-Gohrke</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cramer</surname><given-names>Daniel W.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Terry</surname><given-names>Kathryn L.</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hankinson</surname><given-names>Susan E.</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref><xref ref-type="aff" rid="aff12"><sup>12</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tworoger</surname><given-names>Shelley S.</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref><xref ref-type="aff" rid="aff12"><sup>12</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Garcia-Closas</surname><given-names>Montserrat</given-names></name><xref ref-type="aff" rid="aff13"><sup>13</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="aff13"><sup>13</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lissowska</surname><given-names>Jolanta</given-names></name><xref ref-type="aff" rid="aff14"><sup>14</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chanock</surname><given-names>Stephen J.</given-names></name><xref ref-type="aff" rid="aff15"><sup>15</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pharoah</surname><given-names>Paul D.</given-names></name><xref ref-type="aff" rid="aff16"><sup>16</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Song</surname><given-names>Honglin</given-names></name><xref ref-type="aff" rid="aff16"><sup>16</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Whitemore</surname><given-names>Alice S.</given-names></name><xref ref-type="aff" rid="aff17"><sup>17</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pearce</surname><given-names>Celeste L.</given-names></name><xref ref-type="aff" rid="aff18"><sup>18</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Stram</surname><given-names>Daniel O.</given-names></name><xref ref-type="aff" rid="aff18"><sup>18</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>Anna H.</given-names></name><xref ref-type="aff" rid="aff18"><sup>18</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pike</surname><given-names>Malcolm C.</given-names></name><xref ref-type="aff" rid="aff18"><sup>18</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gayther</surname><given-names>Simon A.</given-names></name><xref ref-type="aff" rid="aff19"><sup>19</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ramus</surname><given-names>Susan J.</given-names></name><xref ref-type="aff" rid="aff19"><sup>19</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Menon</surname><given-names>Usha</given-names></name><xref ref-type="aff" rid="aff19"><sup>19</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gentry-Maharaj</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="aff19"><sup>19</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anton-Culver</surname><given-names>Hoda</given-names></name><xref ref-type="aff" rid="aff20"><sup>20</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ziogas</surname><given-names>Argyrios</given-names></name><xref ref-type="aff" rid="aff20"><sup>20</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hogdall</surname><given-names>Estrid</given-names></name><xref ref-type="aff" rid="aff21"><sup>21</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kjaer</surname><given-names>Susanne K.</given-names></name><xref ref-type="aff" rid="aff21"><sup>21</sup></xref><xref ref-type="aff" rid="aff22"><sup>22</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hogdall</surname><given-names>Claus</given-names></name><xref ref-type="aff" rid="aff22"><sup>22</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Berchuck</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff23"><sup>23</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Schildkraut</surname><given-names>Joellen M.</given-names></name><xref ref-type="aff" rid="aff23"><sup>23</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Iversen</surname><given-names>Edwin S.</given-names></name><xref ref-type="aff" rid="aff23"><sup>23</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moorman</surname><given-names>Patricia G.</given-names></name><xref ref-type="aff" rid="aff23"><sup>23</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Phelan</surname><given-names>Catherine M.</given-names></name><xref ref-type="aff" rid="aff24"><sup>24</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sellers</surname><given-names>Thomas A.</given-names></name><xref ref-type="aff" rid="aff24"><sup>24</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cunningham</surname><given-names>Julie M.</given-names></name><xref ref-type="aff" rid="aff25"><sup>25</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vierkant</surname><given-names>Robert A.</given-names></name><xref ref-type="aff" rid="aff25"><sup>25</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rider</surname><given-names>David N.</given-names></name><xref ref-type="aff" rid="aff25"><sup>25</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Goode</surname><given-names>Ellen L.</given-names></name><xref ref-type="aff" rid="aff25"><sup>25</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Haviv</surname><given-names>Izhak</given-names></name><xref ref-type="aff" rid="aff26"><sup>26</sup></xref><xref ref-type="aff" rid="aff27"><sup>27</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chenevix-Trench</surname><given-names>Georgia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><collab xlink:type="simple">Ovarian Cancer Association Consortium</collab><xref ref-type="fn" rid="fn1"><sup>¶</sup></xref></contrib>
</contrib-group><aff id="aff1"><label>1</label><addr-line>Queensland Institute of Medical Research, Brisbane, Australia</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Gynaecological Oncology and Westmead Institute for Cancer Research, University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Peter MacCallum Cancer Centre, East Melbourne, Australia</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>Epidemiology Program, Division of Public Health Services, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>Cancer Research Center of Hawaii, University of Hawaii, Hilo, Hawaii, United States of America</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>University of Texas School of Public Health, Houston, Texas, United States of America</addr-line>       </aff><aff id="aff7"><label>7</label><addr-line>Roswell Park Cancer Center, Buffalo, New York, United States of America</addr-line>       </aff><aff id="aff8"><label>8</label><addr-line>Unit of Genetic Epidemiology, Division of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany</addr-line>       </aff><aff id="aff9"><label>9</label><addr-line>Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany</addr-line>       </aff><aff id="aff10"><label>10</label><addr-line>Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts, United States of America</addr-line>       </aff><aff id="aff11"><label>11</label><addr-line>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America</addr-line>       </aff><aff id="aff12"><label>12</label><addr-line>Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America</addr-line>       </aff><aff id="aff13"><label>13</label><addr-line>National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland, United States of America</addr-line>       </aff><aff id="aff14"><label>14</label><addr-line>Department of Cancer Epidemiology and Prevention, The M. Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland</addr-line>       </aff><aff id="aff15"><label>15</label><addr-line>Laboratory of Translational Genomics Division of Cancer Epidemiology and Genetics National Cancer Institute and Core Genotyping Facility Division of Cancer Epidemiology and Genetics National Cancer Institute, Bethesda, Maryland, United States of America</addr-line>       </aff><aff id="aff16"><label>16</label><addr-line>Department of Oncology and Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom</addr-line>       </aff><aff id="aff17"><label>17</label><addr-line>Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, United States of America</addr-line>       </aff><aff id="aff18"><label>18</label><addr-line>Department of Preventative Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States of America</addr-line>       </aff><aff id="aff19"><label>19</label><addr-line>Department of Gynaecological Oncology, UCL EGA Institute for Women's Health, University College London, London, United Kingdom</addr-line>       </aff><aff id="aff20"><label>20</label><addr-line>Department of Epidemiology, School of Medicine, University of California Irvine, Irvine, California, United States of America</addr-line>       </aff><aff id="aff21"><label>21</label><addr-line>Department of Virus, Hormones, and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark</addr-line>       </aff><aff id="aff22"><label>22</label><addr-line>Gynaecologic Clinic, The Juliane Marie Centre, Righosptalet, University of Copenhagen, Copenhagen, Denmark</addr-line>       </aff><aff id="aff23"><label>23</label><addr-line>Division of Preventative Medicine, The Duke Comprehensive Cancer Center, Durham, North Carolina, United States of America</addr-line>       </aff><aff id="aff24"><label>24</label><addr-line>Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Center and Research Institute, Magnolia Drive, Tampa, Florida, United States of America</addr-line>       </aff><aff id="aff25"><label>25</label><addr-line>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America</addr-line>       </aff><aff id="aff26"><label>26</label><addr-line>The Blood and DNA Profiling Facility, Baker IDI, Melbourne, Australia</addr-line>       </aff><aff id="aff27"><label>27</label><addr-line>Department of Biochemistry, School of Medicine, University of Melbourne, Parkville, Australia</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Dermitzakis</surname><given-names>Emmanouil T.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">University of Geneva Medical School, Switzerland</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">sharonJo@qimr.edu.au</email></corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: ABS AdF PMW MTG GL JCC SEH MGC SJC PDP ASW CLP SAG SJR UM EH AB JMS TAS ELG GCT. Performed the experiments: JB XC NG IH. Analyzed the data: SEJ JB XC SM DLD NG CLP DNR. Contributed reagents/materials/analysis tools: SEJ SM DLD ABS AdF PMW MAR JAD MTG GL PJT LRW RBN KBM JCC SWG DWC KLT SEH SST MGC HY JL SJC PDP HS ASW CLP DOS AMW MCP SAG SJR UM AGM HAC AZ EH SKK CH AB JMS ESI PGM CMP TAS JMC RAV DNR ELG IH GCT. Wrote the paper: SEJ JB GCT.</p></fn>
<fn fn-type="other" id="fn1"><p>¶ Membership of the Ovarian Cancer Association Consortium is provided in the Acknowledgments.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>7</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>8</day><month>7</month><year>2010</year></pub-date><volume>6</volume><issue>7</issue><elocation-id>e1001016</elocation-id><history>
<date date-type="received"><day>18</day><month>12</month><year>2009</year></date>
<date date-type="accepted"><day>3</day><month>6</month><year>2010</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2010</copyright-year><copyright-holder>Johnatty et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
<p>We hypothesized that variants in genes expressed as a consequence of interactions between ovarian cancer cells and the host micro-environment could contribute to cancer susceptibility. We therefore used a two-stage approach to evaluate common single nucleotide polymorphisms (SNPs) in 173 genes involved in stromal epithelial interactions in the Ovarian Cancer Association Consortium (OCAC). In the discovery stage, cases with epithelial ovarian cancer (n = 675) and controls (n = 1,162) were genotyped at 1,536 SNPs using an Illumina GoldenGate assay. Based on Positive Predictive Value estimates, three SNPs—<italic>PODXL</italic> rs1013368, <italic>ITGA6</italic> rs13027811, and <italic>MMP3</italic> rs522616—were selected for replication using TaqMan genotyping in up to 3,059 serous invasive cases and 8,905 controls from 16 OCAC case-control studies. An additional 18 SNPs with <italic>P</italic><sub>per-allele</sub>&lt;0.05 in the discovery stage were selected for replication in a subset of five OCAC studies (n = 1,233 serous invasive cases; n = 3,364 controls). The discovery stage associations in <italic>PODXL</italic>, <italic>ITGA6</italic>, and <italic>MMP3</italic> were attenuated in the larger replication set (adj. <italic>P</italic><sub>per-allele</sub>≥0.5). However genotypes at <italic>TERT</italic> rs7726159 were associated with ovarian cancer risk in the smaller, five-study replication study (<italic>P</italic><sub>per-allele</sub> = 0.03). Combined analysis of the discovery and replication sets for this <italic>TERT</italic> SNP showed an increased risk of serous ovarian cancer among non-Hispanic whites [adj. OR<sub>per-allele</sub> 1.14 (1.04–1.24) <italic>p</italic> = 0.003]. Our study adds to the growing evidence that, like the 8q24 locus, the telomerase reverse transcriptase locus at 5p15.33, is a general cancer susceptibility locus.</p>
</abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>In this article, we report the findings from a large-scale analysis of common variation in genes that are expressed as a consequence of interactions between ovarian cancer cells and their host micro-environment that could influence serous ovarian cancer risk. We evaluated 1,302 common variants within or near 173 genes in two large case-control studies from the Ovarian Cancer Association Consortium (OCAC) and selected three variants for further evaluation in sixteen OCAC studies and an additional 18 for evaluation in five OCAC studies. We observed a significantly increased risk of serous ovarian cancer associated with a variant in the telomerase reverse transcriptase (<italic>TERT</italic>) gene. Although <italic>TERT</italic> variants have not been previously shown to contribute to ovarian cancer risk, several studies have recently reported associations between <italic>TERT</italic> variants and other forms of cancer, including gliomas, lung cancer, adenocarcinoma, basal cell carcinoma, prostate cancer, and multiple other cancers. <italic>TERT</italic> encodes a protein that is essential for the replication and maintenance of chromosomal integrity during cell division. In cancer cells, <italic>TERT</italic> has been linked to genomic instability and tumour cell proliferation. Further studies are necessary to confirm our findings and to investigate the mechanisms for the observed association.</p>
</abstract><funding-group><funding-statement>ACS/AOCS - National Health and Medical Research Council of Australia (#199600, ACS study; GC-T and PMW); U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, Award no. W81XWH-06-1-0220; the Cancer Council Tasmania and Cancer Foundation of Western Australia; Westmead Millennium Foundation and the Westmead Gynaecological Oncology Research Fund, Westmead Hospital, Westmead, NSW, Australia (NG). DOVE - NIH R01CA112523 and RO1 CA87538. HOPE - National Cancer Institute, Award number R01CA095023. The GER (German Ovarian Cancer Study or GOCS) was supported by the German Federal Ministry of Education and Research of Germany, Programme of Clinical Biomedical Research grant 01 GB 9401, the genotyping in part by the state of Baden-Württemberg through Medical Faculty of the University of Ulm (P.685) and data management by the German Cancer Research Center. UCI - National Cancer Institute grants CA-58860, CA-92044 and the Lon V. Smith Foundation grant LVS-39420. NECC - National Cancer Institute R01CA54419 and P50CA105009. MAY - National Institutes of Health R01-CA122443. PBCS (POL) - Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. HAWAII - US Public Health Service grant R01-CA-58598, and contracts N01-CN-55424 and N01-PC-67001 from the National Cancer Institute, NIH, Department of Health and Human Services. SEARCH - programme grant from Cancer Research UK. UKOPS - The work of SAG, SJR, AG-M, and UM was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The UKOPS study was funded by the Oak Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Ovarian cancer is the seventh leading cause of cancer mortality among women globally, accounting for 4.2% of cancer deaths <xref ref-type="bibr" rid="pgen.1001016-Parkin1">[1]</xref>, due in part to the lack of practical screening methods and detectable symptoms in the early stages of tumor progression <xref ref-type="bibr" rid="pgen.1001016-Wenham1">[2]</xref>. Although the aetiology of ovarian cancer has not been fully elucidated, it is generally agreed that family history of ovarian or breast cancer is the most important risk factor for epithelial ovarian cancer <xref ref-type="bibr" rid="pgen.1001016-Whittemore1">[3]</xref>. Hereditary ovarian cancer occurring in breast/ovarian cancer families has been linked to mutations in the <italic>BRCA1</italic> and <italic>BRCA2</italic> genes, while cases occurring in association with Lynch syndrome have been linked to mutations in <italic>MSH2</italic> and <italic>MLH1</italic> <xref ref-type="bibr" rid="pgen.1001016-Pharoah1">[4]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Boyd1">[5]</xref>. Given that only 3% to 5% of ovarian cancer cases present from high-risk families and residual family history associations <xref ref-type="bibr" rid="pgen.1001016-Wenham1">[2]</xref>, it is likely that several low-penetrance genes with relatively common alleles that confer slightly increased risk may account for a portion of the risk of non-familial ovarian cancer. The Ovarian Cancer Association Consortium (OCAC) was established in 2005 to provide a forum for the identification and validation of common low-penetrance ovarian cancer susceptibility polymorphisms with increased power <xref ref-type="bibr" rid="pgen.1001016-Gayther1">[6]</xref>. OCAC recently conducted a genome-wide association study (GWAS) and identified the first susceptibility locus associated with invasive ovarian cancer risk <xref ref-type="bibr" rid="pgen.1001016-Song1">[7]</xref>.</p>
<p>A number of hypotheses have been put forward to explain the pathogenesis of ovarian cancer <xref ref-type="bibr" rid="pgen.1001016-Risch1">[8]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Riman1">[9]</xref>, including that of incessant ovulation which causes repeated minor trauma to the surface of the ovary, leading to proliferation of ovarian epithelium and repair of the ovulatory wound <xref ref-type="bibr" rid="pgen.1001016-Fathalla1">[10]</xref>. However, it has also been hypothesized that fallopian tube epithelial cells migrating to the ovulatory wound could serve as precursors to ovarian cancer <xref ref-type="bibr" rid="pgen.1001016-Fleming1">[11]</xref>. Research in the past two decades compellingly suggests that the neighbors of cancer cells, collectively termed stroma, are not uninvolved bystanders <xref ref-type="bibr" rid="pgen.1001016-Cunha1">[12]</xref> and studies involving three-dimensional cell culture models underscore the involvement of the extracellular matrix surrounding cancer cells in the signalling pathways that promote cell survival <xref ref-type="bibr" rid="pgen.1001016-Jacks1">[13]</xref>. Fibroblasts with a carcinoma-promoting phenotype [carcinoma-associated fibroblasts (CAFs)] residing in the breast cancer microenvironment lack the ability of normal fibroblasts to attenuate the growth of neighbouring transformed epithelial cells <xref ref-type="bibr" rid="pgen.1001016-Sadlonova1">[14]</xref>. In addition, xenograft models have shown that CAFs accelerate cancer progression through their ability to secrete stromal cell-derived factor 1 <xref ref-type="bibr" rid="pgen.1001016-Orimo1">[15]</xref>. Furthermore, expression profiling of ovarian tumor samples has identified a group of high-grade invasive cancers characterized by a reactive stromal gene expression signature and extensive desmoplasia, which confer an inherently poor prognosis <xref ref-type="bibr" rid="pgen.1001016-Tothill1">[16]</xref>. If this CAF-dependent model of tumorigenesis is correct, it assigns a key role to the neighboring stroma in cancer initiation.</p>
<p>We therefore hypothesized that subtle variation in the expression or function of genes expressed as a consequence of interactions between ovarian cancer cells and the host micro-environment could contribute to ovarian cancer susceptibility. We used a two-stage approach to comprehensively evaluate common variation in 173 genes selected for their putative role in stromal-epithelial interactions using a tagging-SNP approach and data from sixteen case-control studies participating in the Ovarian Cancer Association Consortium (OCAC).</p>
</sec><sec id="s2">
<title>Results</title>
<p>Candidate gene selection and justification are provided in <xref ref-type="supplementary-material" rid="pgen.1001016.s006">Text S1</xref> and <xref ref-type="supplementary-material" rid="pgen.1001016.s002">Table S1</xref>. Characteristics of all case-control studies that contributed data to discovery and replication analyses are provided in <xref ref-type="supplementary-material" rid="pgen.1001016.s003">Table S2</xref>. Comparison of the mean age at diagnosis for cases and age at interview for controls showed that cases were significantly older compared to controls (<italic>p</italic>&lt;0.05). <xref ref-type="supplementary-material" rid="pgen.1001016.s001">Figure S1</xref> provides an overview of SNP and cases-controls numbers analysed in the discovery and replication stages of this study. Discovery samples consisted of serous invasive cases from the AUS (550 cases and 1,101 controls) and MAY (125 cases and 61 controls; all non-Hispanic Whites) studies. AUS participants were not selected for ethnicity, but comprised of predominantly non-Hispanic White women. Of the 1,837 women with genotype data, three were excluded by PLINK default thresholds because &gt;10% of SNPs failed genotyping for these individuals. Of the 1,536 single nucleotide polymorphisms (SNPs) genotyped, 1,309 SNPs passed our initial quality control (QC) criteria, and of these, seven were excluded by PLINK default thresholds. The remaining 1,302 SNPs were subject to further pruning as follows: 37 SNPs with significantly different frequencies of missing genotype data between cases and controls (<italic>P</italic><sub>Miss</sub>&lt;0.05); 296 SNPs with duplicate discordance and/or failure to meet Hardy-Weinberg equilibrium (HWE) criteria (0.001&lt;<italic>P<sub>HWE</sub></italic>&lt;0.05). Of the remaining 969 SNPs analysed in the discovery stage, 59 SNPs with <italic>P</italic><sub>Trend</sub>&lt;0.05 were considered for the replication study (see <xref ref-type="supplementary-material" rid="pgen.1001016.s004">Table S3</xref>).</p>
<p>Based on positive predictive value (PPV) estimates, the three SNPs selected for replication using TaqMan genotyping by the 16 OCAC studies were <italic>PODXL</italic> (podocalyxin-like) rs1013368 (PPV 33.1%), <italic>ITGA6</italic> (integrin, alpha 6) rs13027811 (PPV 4.5%) and <italic>MMP3</italic> (matrix metallopeptidase 3) rs522616 (PPV 4.4%) (<xref ref-type="table" rid="pgen-1001016-t001">Table 1</xref>). These 16 OCAC studies included all histologic subtypes, and ethnicities. An additional 18 SNPs with <italic>P</italic><sub>Trend</sub>&lt;0.05 which fitted into the iPLEX design were selected for replication by a subset of five of the 16 OCAC studies [AUS (additional samples not in the discovery set), MAL, SEA, UKO, and USC]. <italic>FGF2</italic> rs17473132 included among the 18 selected SNPs (<italic>P</italic><sub>Trend</sub> = 0.008) has been previously reported elsewhere <xref ref-type="bibr" rid="pgen.1001016-Johnatty1">[17]</xref> and is therefore excluded from this report. Replication sample sizes varied by SNP depending on which participating OCAC study met QC criteria; MAY, NCO, NEC and NHS failed QC for <italic>PODXL</italic> rs1013368, and GER and STA failed QC for <italic>ITGA6</italic> rs13027811. <xref ref-type="table" rid="pgen-1001016-t002">Table 2</xref> provides the risk estimates adjusted for age and study site for SNPs included in the replication analysis. There was no evidence of between-study heterogeneity for any replication SNP with the exception of <italic>TERT</italic> rs7726159 (<italic>p</italic> = 0.005) (<xref ref-type="supplementary-material" rid="pgen.1001016.s005">Table S4</xref>). Further examination of the site-specific Odds Ratios (ORs) showed that this was driven in part by the smaller USC study, the exclusion of which resulted in a <italic>p</italic>-value for between-study heterogeneity of 0.09. The associations observed in the discovery set for the three SNPs selected based on PPV values (<italic>PODXL</italic> rs1013368, <italic>ITGA6</italic> rs13027811, and <italic>MMP3</italic> rs522616), were completely attenuated in the larger replication analysis of 16 case control studies (adj. <italic>P</italic><sub>per-allele</sub>≥0.5) (<xref ref-type="table" rid="pgen-1001016-t002">Table 2</xref>).</p>
<table-wrap id="pgen-1001016-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pgen.1001016.t001</object-id><label>Table 1</label><caption>
<title>Discovery analysis: risk estimates for serous ovarian cancer for three SNPs selected for replication by 16 OCAC studies.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pgen-1001016-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.t001" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Gene symbol</td>
<td align="left" colspan="1" rowspan="1">CHR</td>
<td align="left" colspan="1" rowspan="1">SNP</td>
<td align="left" colspan="1" rowspan="1">Minor Allele</td>
<td align="left" colspan="1" rowspan="1">Major Allele</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt101">a</xref>MAF</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt101">a</xref><italic>P</italic><sub>HWE</sub></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt102">b</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt102">b</xref><italic>P</italic><sub>allelic</sub></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt103">c</xref><italic>P</italic><sub>Trend</sub></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt104">d</xref>Power</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt105">e</xref>PPV</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PODXL</italic></td>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">rs1013368</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">0.34</td>
<td align="left" colspan="1" rowspan="1">1.00</td>
<td align="left" colspan="1" rowspan="1">1.32</td>
<td align="left" colspan="1" rowspan="1">(1.14–1.51)</td>
<td align="left" colspan="1" rowspan="1">0.0001126</td>
<td align="left" colspan="1" rowspan="1">0.0001037</td>
<td align="left" colspan="1" rowspan="1">0.51</td>
<td align="left" colspan="1" rowspan="1">33.1%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>ITGA6</italic></td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">rs13027811</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">0.12</td>
<td align="left" colspan="1" rowspan="1">0.87</td>
<td align="left" colspan="1" rowspan="1">0.68</td>
<td align="left" colspan="1" rowspan="1">(0.54–0.85)</td>
<td align="left" colspan="1" rowspan="1">0.0008275</td>
<td align="left" colspan="1" rowspan="1">0.0008566</td>
<td align="left" colspan="1" rowspan="1">0.40</td>
<td align="left" colspan="1" rowspan="1">4.5%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>MMP3</italic></td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">rs522616</td>
<td align="left" colspan="1" rowspan="1">G</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">0.23</td>
<td align="left" colspan="1" rowspan="1">0.93</td>
<td align="left" colspan="1" rowspan="1">0.76</td>
<td align="left" colspan="1" rowspan="1">(0.64–0.90)</td>
<td align="left" colspan="1" rowspan="1">0.001178</td>
<td align="left" colspan="1" rowspan="1">0.001184</td>
<td align="left" colspan="1" rowspan="1">0.55</td>
<td align="left" colspan="1" rowspan="1">4.4%</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt101"><label/><p><sup><bold>a</bold></sup>MAF and <italic>P</italic><sub>HWE</sub> derived from controls.</p></fn><fn id="nt102"><label/><p><sup><bold>b</bold></sup>Odds ratios, 95% CI and p-values are derived from the allelic test for association using χ<sup>2</sup> test on 1 df.</p></fn><fn id="nt103"><label/><p><sup><bold>c</bold></sup>Cochran-Armitage trend test (1df).</p></fn><fn id="nt104"><label/><p><sup><bold>d</bold></sup>Power of the study to detect the association.</p></fn><fn id="nt105"><label/><p><sup><bold>e</bold></sup>Positive predictive value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pgen-1001016-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pgen.1001016.t002</object-id><label>Table 2</label><caption>
<title>Replication analysis: risk estimates for serous invasive ovarian cancer in non-Hispanic whites for SNPs selected for replication by indicated OCAC sites.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pgen-1001016-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.t002" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Gene</td>
<td align="left" colspan="1" rowspan="1">SNP</td>
<td align="left" colspan="1" rowspan="1">MAF<xref ref-type="table-fn" rid="nt106">a</xref></td>
<td align="left" colspan="1" rowspan="1">Controls</td>
<td align="left" colspan="1" rowspan="1">Cases</td>
<td align="left" colspan="1" rowspan="1">OR<sub>Het</sub><xref ref-type="table-fn" rid="nt107">b</xref></td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1">OR<sub>Hom</sub><xref ref-type="table-fn" rid="nt107">b</xref></td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1">OR<sub>per-allele</sub><xref ref-type="table-fn" rid="nt107">b</xref></td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1">OCAC Studies<xref ref-type="table-fn" rid="nt108">c</xref></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PODXL</italic></td>
<td align="left" colspan="1" rowspan="1">rs1013368</td>
<td align="left" colspan="1" rowspan="1">0.38</td>
<td align="left" colspan="1" rowspan="1">6,308</td>
<td align="left" colspan="1" rowspan="1">2,173</td>
<td align="left" colspan="1" rowspan="1">1.00</td>
<td align="left" colspan="1" rowspan="1">(0.89–1.10)</td>
<td align="left" colspan="1" rowspan="1">0.88</td>
<td align="left" colspan="1" rowspan="1">1.02</td>
<td align="left" colspan="1" rowspan="1">(0.88–1.18)</td>
<td align="left" colspan="1" rowspan="1">0.81</td>
<td align="left" colspan="1" rowspan="1">1.01</td>
<td align="left" colspan="1" rowspan="1">(0.94–1.08)</td>
<td align="left" colspan="1" rowspan="1">0.88</td>
<td align="left" colspan="1" rowspan="1">AUS, DOV, GER, HAW, HOP, MAL, POL, SEA, STA, UCI, USC, UKO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>ITGA6</italic></td>
<td align="left" colspan="1" rowspan="1">rs13027811</td>
<td align="left" colspan="1" rowspan="1">0.10</td>
<td align="left" colspan="1" rowspan="1">8,005</td>
<td align="left" colspan="1" rowspan="1">2,660</td>
<td align="left" colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">(0.92–1.16)</td>
<td align="left" colspan="1" rowspan="1">0.57</td>
<td align="left" colspan="1" rowspan="1">1.04</td>
<td align="left" colspan="1" rowspan="1">(0.67–1.61)</td>
<td align="left" colspan="1" rowspan="1">0.87</td>
<td align="left" colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">(0.93–1.14)</td>
<td align="left" colspan="1" rowspan="1">0.57</td>
<td align="left" colspan="1" rowspan="1">AUS, DOV, HAW, HOP, MAL, MAY, NCO, NEC, NHS, POL, SEA, UCI, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>MMP3</italic></td>
<td align="left" colspan="1" rowspan="1">rs522616</td>
<td align="left" colspan="1" rowspan="1">0.20</td>
<td align="left" colspan="1" rowspan="1">8,773</td>
<td align="left" colspan="1" rowspan="1">2,985</td>
<td align="left" colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">(0.94–1.12)</td>
<td align="left" colspan="1" rowspan="1">0.58</td>
<td align="left" colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">(0.84–1.27)</td>
<td align="left" colspan="1" rowspan="1">0.74</td>
<td align="left" colspan="1" rowspan="1">1.02</td>
<td align="left" colspan="1" rowspan="1">(0.96–1.10)</td>
<td align="left" colspan="1" rowspan="1">0.55</td>
<td align="left" colspan="1" rowspan="1">AUS, DOV, GER, HAW, HOP, MAL, MAY, NCO, NEC, NHS, POL, SEA, STA, UCI, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PODXL</italic></td>
<td align="left" colspan="1" rowspan="1">rs11768640</td>
<td align="left" colspan="1" rowspan="1">0.24</td>
<td align="left" colspan="1" rowspan="1">2,952</td>
<td align="left" colspan="1" rowspan="1">1,076</td>
<td align="left" colspan="1" rowspan="1">0.92</td>
<td align="left" colspan="1" rowspan="1">(0.79–1.06)</td>
<td align="left" colspan="1" rowspan="1">0.25</td>
<td align="left" colspan="1" rowspan="1">0.86</td>
<td align="left" colspan="1" rowspan="1">(0.62–1.18)</td>
<td align="left" colspan="1" rowspan="1">0.35</td>
<td align="left" colspan="1" rowspan="1">0.92</td>
<td align="left" colspan="1" rowspan="1">(0.82–1.04)</td>
<td align="left" colspan="1" rowspan="1">0.17</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PODXL</italic></td>
<td align="left" colspan="1" rowspan="1">rs4731799</td>
<td align="left" colspan="1" rowspan="1">0.47</td>
<td align="left" colspan="1" rowspan="1">2,954</td>
<td align="left" colspan="1" rowspan="1">1,077</td>
<td align="left" colspan="1" rowspan="1">0.94</td>
<td align="left" colspan="1" rowspan="1">(0.80–1.11)</td>
<td align="left" colspan="1" rowspan="1">0.48</td>
<td align="left" colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">(0.85–1.25)</td>
<td align="left" colspan="1" rowspan="1">0.75</td>
<td align="left" colspan="1" rowspan="1">1.01</td>
<td align="left" colspan="1" rowspan="1">(0.92–1.12)</td>
<td align="left" colspan="1" rowspan="1">0.82</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>ITGA6</italic></td>
<td align="left" colspan="1" rowspan="1">rs1574028</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
<td align="left" colspan="1" rowspan="1">2,958</td>
<td align="left" colspan="1" rowspan="1">1,080</td>
<td align="left" colspan="1" rowspan="1">1.00</td>
<td align="left" colspan="1" rowspan="1">(0.83–1.21)</td>
<td align="left" colspan="1" rowspan="1">0.98</td>
<td align="left" colspan="1" rowspan="1">1.10</td>
<td align="left" colspan="1" rowspan="1">(0.54–2.23)</td>
<td align="left" colspan="1" rowspan="1">0.79</td>
<td align="left" colspan="1" rowspan="1">1.01</td>
<td align="left" colspan="1" rowspan="1">(0.85–1.20)</td>
<td align="left" colspan="1" rowspan="1">0.89</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold><italic>MMP7</italic></bold></td>
<td align="left" colspan="1" rowspan="1"><bold>rs17098236</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.08</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>2,945</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1,074</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.14</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(0.95–1.37)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.17</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>2.34</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.04–5.26)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.04</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.19</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.01–1.42)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.04</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>AUS, MAL, SEA, UKO, USC</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>MMP26</italic></td>
<td align="left" colspan="1" rowspan="1">rs11035042</td>
<td align="left" colspan="1" rowspan="1">0.11</td>
<td align="left" colspan="1" rowspan="1">2,957</td>
<td align="left" colspan="1" rowspan="1">1,080</td>
<td align="left" colspan="1" rowspan="1">1.04</td>
<td align="left" colspan="1" rowspan="1">(0.88–1.24)</td>
<td align="left" colspan="1" rowspan="1">0.63</td>
<td align="left" colspan="1" rowspan="1">0.63</td>
<td align="left" colspan="1" rowspan="1">(0.30–1.31)</td>
<td align="left" colspan="1" rowspan="1">0.21</td>
<td align="left" colspan="1" rowspan="1">0.99</td>
<td align="left" colspan="1" rowspan="1">(0.84–1.16)</td>
<td align="left" colspan="1" rowspan="1">0.89</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>FN1</italic></td>
<td align="left" colspan="1" rowspan="1">rs1250229</td>
<td align="left" colspan="1" rowspan="1">0.26</td>
<td align="left" colspan="1" rowspan="1">2,954</td>
<td align="left" colspan="1" rowspan="1">1,075</td>
<td align="left" colspan="1" rowspan="1">0.92</td>
<td align="left" colspan="1" rowspan="1">(0.79–1.07)</td>
<td align="left" colspan="1" rowspan="1">0.26</td>
<td align="left" colspan="1" rowspan="1">1.01</td>
<td align="left" colspan="1" rowspan="1">(0.76–1.34)</td>
<td align="left" colspan="1" rowspan="1">0.96</td>
<td align="left" colspan="1" rowspan="1">0.96</td>
<td align="left" colspan="1" rowspan="1">(0.86–1.08)</td>
<td align="left" colspan="1" rowspan="1">0.50</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PLOD2</italic></td>
<td align="left" colspan="1" rowspan="1">rs1512900</td>
<td align="left" colspan="1" rowspan="1">0.47</td>
<td align="left" colspan="1" rowspan="1">2,942</td>
<td align="left" colspan="1" rowspan="1">1,070</td>
<td align="left" colspan="1" rowspan="1">0.89</td>
<td align="left" colspan="1" rowspan="1">(0.76–1.05)</td>
<td align="left" colspan="1" rowspan="1">0.16</td>
<td align="left" colspan="1" rowspan="1">0.85</td>
<td align="left" colspan="1" rowspan="1">(0.69–1.04)</td>
<td align="left" colspan="1" rowspan="1">0.11</td>
<td align="left" colspan="1" rowspan="1">0.92</td>
<td align="left" colspan="1" rowspan="1">(0.83–1.01)</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PANX1</italic></td>
<td align="left" colspan="1" rowspan="1">rs1540177</td>
<td align="left" colspan="1" rowspan="1">0.40</td>
<td align="left" colspan="1" rowspan="1">2,956</td>
<td align="left" colspan="1" rowspan="1">1,079</td>
<td align="left" colspan="1" rowspan="1">0.94</td>
<td align="left" colspan="1" rowspan="1">(0.80–1.10)</td>
<td align="left" colspan="1" rowspan="1">0.42</td>
<td align="left" colspan="1" rowspan="1">1.18</td>
<td align="left" colspan="1" rowspan="1">(0.96–1.45)</td>
<td align="left" colspan="1" rowspan="1">0.12</td>
<td align="left" colspan="1" rowspan="1">1.06</td>
<td align="left" colspan="1" rowspan="1">(0.96–1.17)</td>
<td align="left" colspan="1" rowspan="1">0.28</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PTTG1</italic></td>
<td align="left" colspan="1" rowspan="1">rs17057781</td>
<td align="left" colspan="1" rowspan="1">0.14</td>
<td align="left" colspan="1" rowspan="1">2,954</td>
<td align="left" colspan="1" rowspan="1">1,079</td>
<td align="left" colspan="1" rowspan="1">1.04</td>
<td align="left" colspan="1" rowspan="1">(0.88–1.22)</td>
<td align="left" colspan="1" rowspan="1">0.67</td>
<td align="left" colspan="1" rowspan="1">1.32</td>
<td align="left" colspan="1" rowspan="1">(0.82–2.15)</td>
<td align="left" colspan="1" rowspan="1">0.25</td>
<td align="left" colspan="1" rowspan="1">1.07</td>
<td align="left" colspan="1" rowspan="1">(0.93–1.23)</td>
<td align="left" colspan="1" rowspan="1">0.36</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>CSF1</italic></td>
<td align="left" colspan="1" rowspan="1">rs1999713</td>
<td align="left" colspan="1" rowspan="1">0.35</td>
<td align="left" colspan="1" rowspan="1">2,957</td>
<td align="left" colspan="1" rowspan="1">1,076</td>
<td align="left" colspan="1" rowspan="1">0.95</td>
<td align="left" colspan="1" rowspan="1">(0.82–1.11)</td>
<td align="left" colspan="1" rowspan="1">0.54</td>
<td align="left" colspan="1" rowspan="1">1.09</td>
<td align="left" colspan="1" rowspan="1">(0.87–1.36)</td>
<td align="left" colspan="1" rowspan="1">0.45</td>
<td align="left" colspan="1" rowspan="1">1.02</td>
<td align="left" colspan="1" rowspan="1">(0.92–1.13)</td>
<td align="left" colspan="1" rowspan="1">0.75</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>PTEN</italic></td>
<td align="left" colspan="1" rowspan="1">rs34370136</td>
<td align="left" colspan="1" rowspan="1">0.06</td>
<td align="left" colspan="1" rowspan="1">2,957</td>
<td align="left" colspan="1" rowspan="1">1,079</td>
<td align="left" colspan="1" rowspan="1">0.86</td>
<td align="left" colspan="1" rowspan="1">(0.68–1.09)</td>
<td align="left" colspan="1" rowspan="1">0.22</td>
<td align="left" colspan="1" rowspan="1">0.53</td>
<td align="left" colspan="1" rowspan="1">(0.12–2.44)</td>
<td align="left" colspan="1" rowspan="1">0.42</td>
<td align="left" colspan="1" rowspan="1">0.85</td>
<td align="left" colspan="1" rowspan="1">(0.68–1.06)</td>
<td align="left" colspan="1" rowspan="1">0.15</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>LCN2</italic></td>
<td align="left" colspan="1" rowspan="1">rs3814526</td>
<td align="left" colspan="1" rowspan="1">0.04</td>
<td align="left" colspan="1" rowspan="1">2,957</td>
<td align="left" colspan="1" rowspan="1">1,079</td>
<td align="left" colspan="1" rowspan="1">1.20</td>
<td align="left" colspan="1" rowspan="1">(0.94–1.52)</td>
<td align="left" colspan="1" rowspan="1">0.14</td>
<td align="left" colspan="1" rowspan="1">0.38</td>
<td align="left" colspan="1" rowspan="1">(0.05–3.12)</td>
<td align="left" colspan="1" rowspan="1">0.37</td>
<td align="left" colspan="1" rowspan="1">1.14</td>
<td align="left" colspan="1" rowspan="1">(0.91–1.44)</td>
<td align="left" colspan="1" rowspan="1">0.25</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>TIMP3</italic></td>
<td align="left" colspan="1" rowspan="1">rs5754289</td>
<td align="left" colspan="1" rowspan="1">0.17</td>
<td align="left" colspan="1" rowspan="1">2,942</td>
<td align="left" colspan="1" rowspan="1">1,076</td>
<td align="left" colspan="1" rowspan="1">1.02</td>
<td align="left" colspan="1" rowspan="1">(0.87–1.19)</td>
<td align="left" colspan="1" rowspan="1">0.81</td>
<td align="left" colspan="1" rowspan="1">0.93</td>
<td align="left" colspan="1" rowspan="1">(0.62–1.41)</td>
<td align="left" colspan="1" rowspan="1">0.74</td>
<td align="left" colspan="1" rowspan="1">1.00</td>
<td align="left" colspan="1" rowspan="1">(0.88–1.14)</td>
<td align="left" colspan="1" rowspan="1">0.99</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>DDR2</italic></td>
<td align="left" colspan="1" rowspan="1">rs6693632</td>
<td align="left" colspan="1" rowspan="1">0.05</td>
<td align="left" colspan="1" rowspan="1">2,954</td>
<td align="left" colspan="1" rowspan="1">1,080</td>
<td align="left" colspan="1" rowspan="1">0.86</td>
<td align="left" colspan="1" rowspan="1">(0.67–1.12)</td>
<td align="left" colspan="1" rowspan="1">0.27</td>
<td align="left" colspan="1" rowspan="1">0.36</td>
<td align="left" colspan="1" rowspan="1">(0.04–2.93)</td>
<td align="left" colspan="1" rowspan="1">0.34</td>
<td align="left" colspan="1" rowspan="1">0.84</td>
<td align="left" colspan="1" rowspan="1">(0.66–1.08)</td>
<td align="left" colspan="1" rowspan="1">0.18</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>DDR2</italic></td>
<td align="left" colspan="1" rowspan="1">rs6702820</td>
<td align="left" colspan="1" rowspan="1">0.24</td>
<td align="left" colspan="1" rowspan="1">2,954</td>
<td align="left" colspan="1" rowspan="1">1,080</td>
<td align="left" colspan="1" rowspan="1">0.88</td>
<td align="left" colspan="1" rowspan="1">(0.76–1.02)</td>
<td align="left" colspan="1" rowspan="1">0.09</td>
<td align="left" colspan="1" rowspan="1">0.89</td>
<td align="left" colspan="1" rowspan="1">(0.64–1.22)</td>
<td align="left" colspan="1" rowspan="1">0.46</td>
<td align="left" colspan="1" rowspan="1">0.91</td>
<td align="left" colspan="1" rowspan="1">(0.80–1.02)</td>
<td align="left" colspan="1" rowspan="1">0.10</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><italic>DDR2</italic></td>
<td align="left" colspan="1" rowspan="1">rs10917589</td>
<td align="left" colspan="1" rowspan="1">0.07</td>
<td align="left" colspan="1" rowspan="1">2,955</td>
<td align="left" colspan="1" rowspan="1">1,079</td>
<td align="left" colspan="1" rowspan="1">1.00</td>
<td align="left" colspan="1" rowspan="1">(0.81–1.24)</td>
<td align="left" colspan="1" rowspan="1">0.97</td>
<td align="left" colspan="1" rowspan="1">1.62</td>
<td align="left" colspan="1" rowspan="1">(0.74–3.56)</td>
<td align="left" colspan="1" rowspan="1">0.23</td>
<td align="left" colspan="1" rowspan="1">1.05</td>
<td align="left" colspan="1" rowspan="1">(0.87–1.27)</td>
<td align="left" colspan="1" rowspan="1">0.59</td>
<td align="left" colspan="1" rowspan="1">AUS, MAL, SEA, UKO, USC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold><italic>TERT</italic></bold></td>
<td align="left" colspan="1" rowspan="1"><bold>rs7726159</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.33</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>2,952</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1,079</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.18</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.02–1.37)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.03</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.21</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(0.95–1.53)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.12</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.12</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.01–1.25)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.03</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>AUS, MAL, SEA, UKO, USC</bold></td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt106"><label/><p><sup><bold>a</bold></sup>MAF in controls.</p></fn><fn id="nt107"><label/><p><sup><bold>b</bold></sup>ORs, 95% CI and p-values are adjusted for age (at interview in controls, at diagnosis in cases) and study site.</p></fn><fn id="nt108"><label/><p><sup><bold>c</bold></sup>OCAC studies not listed for <italic>PODXL</italic> rs1013368, <italic>ITGA6</italic> rs13027811 and <italic>MMP3</italic> rs522616 were excluded from analysis because of QC failures.</p></fn></table-wrap-foot></table-wrap>
<p>However, adjusted log additive estimates for <italic>TERT</italic> (telomerase reverse transcriptase) rs7726159 retained a statistically significant <italic>p</italic>-value in the replication study of non-Hispanic White serous invasive cases and controls (<italic>P</italic><sub>per-allele</sub> = 0.03), and showed evidence of log additive effects across genotypes. We re-analysed this SNP combining discovery and replication data and observed some evidence of between-study heterogeneity (<italic>p</italic> = 0.027) which again improved with the exclusion of the smaller studies (USC and MAY; <italic>p</italic> = 0.16). Risk estimates for serous invasive ovarian cancer adjusted for age and study site remained statistically significant in the combined dataset [adj. OR<sub>per-allele</sub> 1.14 (1.04–1.24) <italic>p</italic> = 0.003; <xref ref-type="table" rid="pgen-1001016-t003">Table 3</xref>]. Likewise, in exploratory analyses of genotype data on all ethnicities stratified by histological subtype, a increased risk associated with this SNP was observed for serous invasive cases in models adjusted for age, site and ethnicity [adj. OR<sub>per-allele</sub> 1.17 (1.08–1.27) <italic>p</italic> = 7.21×10<sup>−5</sup>]. <italic>TERT</italic> rs7726159 was also associated with serous borderline tumors, but not with any other invasive or borderline subtypes (<xref ref-type="table" rid="pgen-1001016-t004">Table 4</xref>, and <xref ref-type="fig" rid="pgen-1001016-g001">Figure 1</xref>). For <italic>MMP7</italic> rs17098236, the combined age- and site-adjusted estimate from the log additive model suggested an association with serous ovarian cancer but the point estimates were not in the same direction as those obtained in discovery analysis (0.84 vs.1.19; see <xref ref-type="supplementary-material" rid="pgen.1001016.s004">Table S3</xref> and <xref ref-type="table" rid="pgen-1001016-t002">Table 2</xref>). All other SNPs in the smaller replication study failed to replicate the significant associations observed in the discovery sample.</p>
<fig id="pgen-1001016-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pgen.1001016.g001</object-id><label>Figure 1</label><caption>
<title>Histology-specific adjusted per allele risk estimates for rs7726159 for all ethnicities.</title>
<p>Lines indicate 95% confidence intervals; bolded ORs and 95% CIs indicate statistically significant estimates (<italic>P</italic>&lt;0.05); size of the solid box is the proportionate sample size for each histology sub-group with genotype data.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.g001" xlink:type="simple"/></fig><table-wrap id="pgen-1001016-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pgen.1001016.t003</object-id><label>Table 3</label><caption>
<title>Combined discovery and replication analysis: site-specific and combined risk estimates for serous ovarian cancer for <italic>TERT</italic> rs7726159 among non-Hispanic whites.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pgen-1001016-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.t003" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="3" rowspan="1">Heterozygotes</td>
<td align="left" colspan="3" rowspan="1">Homozygotes</td>
<td align="left" colspan="3" rowspan="1">Per-allele</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Study</td>
<td align="left" colspan="1" rowspan="1">Controls</td>
<td align="left" colspan="1" rowspan="1">Serous Cases</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt109">a</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt109">a</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt109">a</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">SEA</td>
<td align="left" colspan="1" rowspan="1">1,213</td>
<td align="left" colspan="1" rowspan="1">383</td>
<td align="left" colspan="1" rowspan="1"><bold>1.35</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.05–1.73)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.019</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.65</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.14–2.38)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.008</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.30</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.10–1.54)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.003</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AUS</td>
<td align="left" colspan="1" rowspan="1">1,202</td>
<td align="left" colspan="1" rowspan="1">636</td>
<td align="left" colspan="1" rowspan="1"><bold>1.30</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.06–1.60)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.012</bold></td>
<td align="left" colspan="1" rowspan="1">1.27</td>
<td align="left" colspan="1" rowspan="1">(0.92–1.76)</td>
<td align="left" colspan="1" rowspan="1">0.148</td>
<td align="left" colspan="1" rowspan="1"><bold>1.18</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.02–1.37)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.025</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MAL</td>
<td align="left" colspan="1" rowspan="1">764</td>
<td align="left" colspan="1" rowspan="1">264</td>
<td align="left" colspan="1" rowspan="1"><bold>1.50</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.10–2.03)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.009</bold></td>
<td align="left" colspan="1" rowspan="1">1.37</td>
<td align="left" colspan="1" rowspan="1">(0.86–2.19)</td>
<td align="left" colspan="1" rowspan="1">0.184</td>
<td align="left" colspan="1" rowspan="1"><bold>1.27</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.03–1.57)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.025</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">UKO</td>
<td align="left" colspan="1" rowspan="1">564</td>
<td align="left" colspan="1" rowspan="1">235</td>
<td align="left" colspan="1" rowspan="1">0.95</td>
<td align="left" colspan="1" rowspan="1">(0.68–1.32)</td>
<td align="left" colspan="1" rowspan="1">0.754</td>
<td align="left" colspan="1" rowspan="1">0.89</td>
<td align="left" colspan="1" rowspan="1">(0.50–1.59)</td>
<td align="left" colspan="1" rowspan="1">0.685</td>
<td align="left" colspan="1" rowspan="1">0.95</td>
<td align="left" colspan="1" rowspan="1">(0.74–1.21)</td>
<td align="left" colspan="1" rowspan="1">0.658</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">USC</td>
<td align="left" colspan="1" rowspan="1">218</td>
<td align="left" colspan="1" rowspan="1">128</td>
<td align="left" colspan="1" rowspan="1">0.71</td>
<td align="left" colspan="1" rowspan="1">(0.45–1.13)</td>
<td align="left" colspan="1" rowspan="1">0.152</td>
<td align="left" colspan="1" rowspan="1">0.53</td>
<td align="left" colspan="1" rowspan="1">(0.24–1.15)</td>
<td align="left" colspan="1" rowspan="1">0.108</td>
<td align="left" colspan="1" rowspan="1">0.72</td>
<td align="left" colspan="1" rowspan="1">(0.51–1.01)</td>
<td align="left" colspan="1" rowspan="1">0.056</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MAY</td>
<td align="left" colspan="1" rowspan="1">61</td>
<td align="left" colspan="1" rowspan="1">125</td>
<td align="left" colspan="1" rowspan="1">1.53</td>
<td align="left" colspan="1" rowspan="1">(0.80–2.94)</td>
<td align="left" colspan="1" rowspan="1">0.198</td>
<td align="left" colspan="1" rowspan="1">0.80</td>
<td align="left" colspan="1" rowspan="1">(0.26–2.40)</td>
<td align="left" colspan="1" rowspan="1">0.684</td>
<td align="left" colspan="1" rowspan="1">1.09</td>
<td align="left" colspan="1" rowspan="1">(0.67–1.78)</td>
<td align="left" colspan="1" rowspan="1">0.732</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Combined (all studies)</bold></td>
<td align="left" colspan="1" rowspan="1">4,022</td>
<td align="left" colspan="1" rowspan="1">1,771</td>
<td align="left" colspan="1" rowspan="1"><bold>1.23</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.09–1.39)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td>
<td align="left" colspan="1" rowspan="1">1.19</td>
<td align="left" colspan="1" rowspan="1">(0.98–1.44)</td>
<td align="left" colspan="1" rowspan="1">0.072</td>
<td align="left" colspan="1" rowspan="1"><bold>1.14</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.04–1.24)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.003</bold></td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt109"><label/><p><sup><bold>a</bold></sup>Estimates are adjusted for age (at interview in controls, at diagnosis in cases) and additionally for study site in combined (all studies) estimates.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pgen-1001016-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pgen.1001016.t004</object-id><label>Table 4</label><caption>
<title>Combined discovery and replication analysis: risk estimates for <italic>TERT</italic> rs7726159 for all races according to tumor behaviour and histological subtypes.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pgen-1001016-t004-4" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.t004" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="3" rowspan="1">Heterozygotes</td>
<td align="left" colspan="3" rowspan="1">Homozygotes</td>
<td align="left" colspan="3" rowspan="1">Per-Allele</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tumor Behavior</td>
<td align="left" colspan="1" rowspan="1">Histological Subtype</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt110">a</xref>Controls</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt110">a</xref>Cases</td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt111">b</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt111">b</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
<td align="left" colspan="1" rowspan="1"><xref ref-type="table-fn" rid="nt111">b</xref>OR</td>
<td align="left" colspan="1" rowspan="1">(95% CI)</td>
<td align="left" colspan="1" rowspan="1"><italic>P</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Invasive</bold></td>
<td align="left" colspan="1" rowspan="1">Serous</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">2196</td>
<td align="left" colspan="1" rowspan="1"><bold>1.30</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.16–1.45)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>5.7×10<sup>−6</sup></bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.25</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.05–1.49)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.011</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.17</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.08–1.27)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>7.21×10<sup>−5</sup></bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1">Mucinous</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">271</td>
<td align="left" colspan="1" rowspan="1">1.15</td>
<td align="left" colspan="1" rowspan="1">(0.88–1.49)</td>
<td align="left" colspan="1" rowspan="1">0.31</td>
<td align="left" colspan="1" rowspan="1">1.01</td>
<td align="left" colspan="1" rowspan="1">(0.66–1.54)</td>
<td align="left" colspan="1" rowspan="1">0.98</td>
<td align="left" colspan="1" rowspan="1">1.05</td>
<td align="left" colspan="1" rowspan="1">(0.87–1.26)</td>
<td align="left" colspan="1" rowspan="1">0.63</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1">Endometrioid</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">454</td>
<td align="left" colspan="1" rowspan="1">0.81</td>
<td align="left" colspan="1" rowspan="1">(0.65–0.99)</td>
<td align="left" colspan="1" rowspan="1">0.045</td>
<td align="left" colspan="1" rowspan="1">1.09</td>
<td align="left" colspan="1" rowspan="1">(0.80–1.48)</td>
<td align="left" colspan="1" rowspan="1">0.57</td>
<td align="left" colspan="1" rowspan="1">0.96</td>
<td align="left" colspan="1" rowspan="1">(0.83–1.12)</td>
<td align="left" colspan="1" rowspan="1">0.64</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1">Clear Cell</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">261</td>
<td align="left" colspan="1" rowspan="1">1.03</td>
<td align="left" colspan="1" rowspan="1">(0.79–1.35)</td>
<td align="left" colspan="1" rowspan="1">0.83</td>
<td align="left" colspan="1" rowspan="1">1.12</td>
<td align="left" colspan="1" rowspan="1">(0.75–1.69)</td>
<td align="left" colspan="1" rowspan="1">0.57</td>
<td align="left" colspan="1" rowspan="1">1.05</td>
<td align="left" colspan="1" rowspan="1">(0.87–1.27)</td>
<td align="left" colspan="1" rowspan="1">0.60</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1">All others</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">355</td>
<td align="left" colspan="1" rowspan="1">1.08</td>
<td align="left" colspan="1" rowspan="1">(0.86–1.37)</td>
<td align="left" colspan="1" rowspan="1">0.50</td>
<td align="left" colspan="1" rowspan="1">1.49</td>
<td align="left" colspan="1" rowspan="1">(0.80–1.64)</td>
<td align="left" colspan="1" rowspan="1">0.45</td>
<td align="left" colspan="1" rowspan="1">1.07</td>
<td align="left" colspan="1" rowspan="1">(0.91–1.26)</td>
<td align="left" colspan="1" rowspan="1">0.38</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Borderline/LMP</bold></td>
<td align="left" colspan="1" rowspan="1">Serous</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">251</td>
<td align="left" colspan="1" rowspan="1"><bold>1.63</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.21–2.18)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>2.04</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.38–3.02)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>0.0004</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>1.46</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>(1.21–1.76)</bold></td>
<td align="left" colspan="1" rowspan="1"><bold>6.63×10<sup>−5</sup></bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1">Mucinous</td>
<td align="left" colspan="1" rowspan="1">4138</td>
<td align="left" colspan="1" rowspan="1">249</td>
<td align="left" colspan="1" rowspan="1">1.13</td>
<td align="left" colspan="1" rowspan="1">(0.85–1.49)</td>
<td align="left" colspan="1" rowspan="1">0.40</td>
<td align="left" colspan="1" rowspan="1">0.85</td>
<td align="left" colspan="1" rowspan="1">(0.53–1.36)</td>
<td align="left" colspan="1" rowspan="1">0.51</td>
<td align="left" colspan="1" rowspan="1">0.99</td>
<td align="left" colspan="1" rowspan="1">(0.81–1.21)</td>
<td align="left" colspan="1" rowspan="1">0.92</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt110"><label/><p><sup><bold>a</bold></sup>Cases and controls derived from AUS, MAL, MAY, SEA, UKO and USC studies.</p></fn><fn id="nt111"><label/><p><sup><bold>b</bold></sup>Estimates are adjusted for age (at interview in controls, at diagnosis in cases), race and study site.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3">
<title>Discussion</title>
<p>Herein we report a large-scale analysis of 1,309 SNPs in 173 genes selected for their putative role in stromal epithelial cross talk, using a two-stage design for assessment of ovarian cancer risk. In the discovery stage we used data from two OCAC case-control studies (AUS and MAY) of predominantly non-Hispanic White women, and observed that SNPs in several genes were associated with risk of serous tumours in unadjusted log-additive models (<xref ref-type="supplementary-material" rid="pgen.1001016.s004">Table S3</xref>). The most significant associations observed (<italic>PODXL</italic> rs1013368, <italic>ITGA6</italic> rs13027811, and <italic>MMP3</italic> rs522616; <italic>P</italic><sub>Trend</sub>≤0.001; <xref ref-type="table" rid="pgen-1001016-t001">Table 1</xref>) were then genotyped in a total of sixteen OCAC studies including additional samples from discovery studies (AUS and MAY), and also from non-serous histologies and all ethnicities. None of these three SNPs were significantly associated with ovarian cancer risk (<italic>P</italic><sub>per-allele</sub>≥0.5). The power of the replication sample to detect the odds ratios observed in the discovery set at a type 1 error rate of 0.05 assuming log additive effects was &gt;99.9% for all three SNPs. Combining discovery and replication data would have provided greater power to detect a significant effect <xref ref-type="bibr" rid="pgen.1001016-Skol1">[18]</xref>, but this was not considered for these SNPs because estimates were unequivocally null in replication analysis and/or in the opposite direction compared to the smaller discovery dataset.</p>
<p>We analysed an additional 18 SNPs, including one in <italic>FGF2</italic> reported elsewhere <xref ref-type="bibr" rid="pgen.1001016-Johnatty1">[17]</xref> in a second smaller replication study using five case-control studies from OCAC, and found evidence of an allelic association between <italic>TERT</italic> rs7726159 and serous tumors (<xref ref-type="table" rid="pgen-1001016-t002">Table 2</xref>). Although the PPV for <italic>TERT</italic> rs7726159 was 1.4%, it was not selected for the larger replication stage in all sixteen OCAC case-control studies because of limited resources. Our estimate from the replication study, adjusted for age and study site, showed an overall 12% increased risk of serous ovarian cancer associated with each minor allele among non-Hispanic Whites. Site-specific estimates were also statistically significant in case-control studies with the largest samples sizes (SEA, AUS and MAL) (<xref ref-type="table" rid="pgen-1001016-t003">Table 3</xref>). We detected significant study heterogeneity in this combined sample of all studies (<italic>p</italic> = 0.027), and this effect was attenuated when the smallest sample sizes (USC and MAY) were removed from the dataset; <italic>p</italic> = 0.16). Inclusion of data on all ethnicities additionally adjusted for race resulted in a significance level (adj. <italic>P</italic><sub>per-allele</sub> = 7.21×10<sup>−5</sup>) that met the conservative Bonferroni adjustment for multiple testing (0.05/21 = adj. <italic>P</italic><sub>per-allele</sub>≤0.0024). In addition, the estimates from log-additive models for <italic>TERT</italic> rs7726159 in the combined discovery and replication non-Hispanic White samples would almost meet Bonferroni adjustment (adj. <italic>P</italic><sub>per-allele</sub> = 0.003).</p>
<p><italic>TERT</italic> encodes the catalytic subunit of telomerase and activation of telomerase has been implicated in human cell immortalization and cancer cell pathogenesis. <italic>TERT</italic> was selected as a candidate gene because it serves as an epithelial stem cell marker <xref ref-type="bibr" rid="pgen.1001016-Campisi1">[19]</xref> and we hypothesized that cross-talk modifies critical aspects of epithelial transformation. <italic>TERT</italic> is a ribonucleoprotein enzyme that maintains telomere ends, and is essential for the replication of chromosomes and suppression of cell senescence. Telomere dysfunction is associated with genomic instability and consequently increased risk of tumor formation <xref ref-type="bibr" rid="pgen.1001016-Feldser1">[20]</xref>. The rs7726159 variant resides in intron 3 of <italic>TERT</italic> and has no obvious functional significance, but it could be in linkage disequilibrium with another functional or causal SNP within the gene. An alternative explanation for the observed association is population stratification, which occurs when allele frequencies differ with population subgroups, or when cases and controls are drawn from different subgroups. We suggest that this is not a likely explanation because cases and controls were drawn from the same source populations within each study, and replication analyses were restricted to non-Hispanic White women or adjusted for ethnicity where applicable. However, it is possible that the association with serous ovarian cancer may vary across populations because of interaction with other genes or environmental factors, and additional studies would be required to confirm these findings.</p>
<p>Although <italic>TERT</italic> variants have not been previously reported to be associated with ovarian cancer, a recent meta-analysis of two GWAS identified another SNP in <italic>TERT</italic>, rs2736100, as significantly associated with gliomas (OR = 1.27; <italic>P</italic> = 1.50×10<sup>−17</sup>) <xref ref-type="bibr" rid="pgen.1001016-Shete1">[21]</xref>. GWAS have found that rs2736100 is also associated with lung cancer (OR = 1.14; <italic>P</italic> = 4×10<sup>−6</sup>) <xref ref-type="bibr" rid="pgen.1001016-McKay1">[22]</xref> and more specifically, with the adenocarcinoma subtype (OR = 1.23; <italic>P</italic> = 3.02×10<sup>−7</sup>) <xref ref-type="bibr" rid="pgen.1001016-Landi1">[23]</xref> (<xref ref-type="fig" rid="pgen-1001016-g002">Figure 2A</xref>). Associations have also been reported between the <italic>TERT- CLPTM1L</italic> (cleft lip and palate transmembrane 1-like gene - cisplatin resistance-related protein 9-) locus and lung cancer (rs402710; OR = 1.17; <italic>P</italic> = 2×10<sup>−7</sup>) <xref ref-type="bibr" rid="pgen.1001016-McKay1">[22]</xref>, basal cell carcinoma (rs401681; OR = 1.20; <italic>P</italic> = 4.8×10<sup>−9</sup>) <xref ref-type="bibr" rid="pgen.1001016-Stacey1">[24]</xref>, pancreatic cancer (rs401681; OR 1.19; (<italic>P</italic> = 3.66×10<sup>−7</sup>) <xref ref-type="bibr" rid="pgen.1001016-Petersen1">[25]</xref>, and multiple cancer types that are known to originate in the epithelium, including bladder, prostate and cervical cancer <xref ref-type="bibr" rid="pgen.1001016-Rafnar1">[26]</xref>. We genotyped rs2736100 in the discovery samples and found a borderline, but inverse, association with serous ovarian cancer [OR = 0.88 (0.77–1.01) <italic>P</italic><sub>Trend</sub> = 0.06]. We also found a borderline association with rs11133719 and serous ovarian cancer risk [OR = 0.81 (0.67–0.98) <italic>P</italic><sub>Trend</sub> = 0.025] in discovery samples. Linkage disequilibrium (LD) estimation between the 11 <italic>TERT</italic> SNPs that we genotyped in stage 1 in 1,047 non-Hispanic White controls showed a moderate pairwise correlation between rs2736100 and rs7726159 (r<sup>2</sup> = 0.43; <xref ref-type="fig" rid="pgen-1001016-g002">Figure 2B</xref>) but rs7726159, which we selected from NIEHS, is not in HapMap and so has not been genotyped in GWAS of ovarian or other cancers. Further analysis of this locus is necessary in order to definitively identify the causal SNP(s) at this locus.</p>
<fig id="pgen-1001016-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pgen.1001016.g002</object-id><label>Figure 2</label><caption>
<title>Gene map and LD plot of <italic>TERT-CLPTM1L</italic> locus and associated SNPs.</title>
<p>Colour scheme is based on r<sup>2</sup> values in Haploview; white r<sup>2</sup> = 0; shades of grey 0&lt;r<sup>2</sup>&lt;1; black r<sup>2</sup> = 1. Block definition is based on the method of Gabriel et al <xref ref-type="bibr" rid="pgen.1001016-Gabriel1">[54]</xref>. (A) Gene map of SNPs genotyped in the discovery stage (underlined) relative to other <italic>TERT</italic> SNPs associated with cancer phenotypes (inset) and LD plot based on HapMap CEU samples. (B) Haploview plot of all <italic>TERT</italic> SNPs genotyped in 1,047 non-Hispanic White controls in our study; numbers in squares are pairwise r<sup>2</sup> values between SNPs.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.g002" xlink:type="simple"/></fig>
<p>To our knowledge, this is the first comprehensive evaluation of genes involved in stromal epithelial cross-talk and serous ovarian cancer. Candidate gene and SNP selection for discovery stage analysis was aimed at optimizing the likelihood of detecting a signal by including tagging and putatively functional SNPs with minor allele frequency (MAF)&gt;5%. Although a tagSNP approach has been shown to improve the power of the study for common variants <xref ref-type="bibr" rid="pgen.1001016-deBakker1">[27]</xref>, modest effects from SNPs with low MAFs may remain undetected. This was illustrated in a recent re-analysis of two SNPs in the <italic>DCN</italic> gene that failed to achieve the minimal <italic>P</italic><sub>Trend</sub>≤0.05 in stage 1 analysis, but conferred a small but significantly decreased risk of serous ovarian cancer in a combined analysis of data from two additional studies <xref ref-type="bibr" rid="pgen.1001016-Amankwah1">[28]</xref>. We therefore suggest caution in interpreting null findings, and the need for large discovery and replication studies. Our discovery study was reasonably well powered, so the failure to find any associations with SNPs in genes involved in stromal epithelial cross-talk, except in <italic>DCN</italic> and <italic>TERT</italic>, suggests that genetic variation in this pathway is not a major determinant of serous ovarian cancer risk.</p>
<p>In summary, we have identified an association between <italic>TERT</italic> rs7726159 and serous ovarian cancer in a large sample of non-Hispanic White women participating in five OCAC case-control studies. We plan to further our investigation of this SNP and others in linkage disequilibrium with it, to determine whether <italic>TERT</italic>, <italic>CLPTM1L</italic> or another gene in the region is the functional target of this association. Our study adds to the growing evidence that, as well as the 8q24 locus <xref ref-type="bibr" rid="pgen.1001016-Shete1">[21]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Easton1">[29]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Gudmundsson1">[30]</xref>–<xref ref-type="bibr" rid="pgen.1001016-Pomerantz1">[32]</xref>, the <italic>TERT-CLPTM1L</italic> locus at 5p15.33, is a general cancer susceptibility locus. This is particularly interesting given the key roles of c-<italic>MYC</italic> (the nearest gene to the 8q24 locus) and <italic>TERT</italic> in tumorigenesis. <italic>TERT</italic> and <italic>MYC</italic> are both expressed in normal and transformed proliferating cells, and can induce immortalization when constitutively expressed <xref ref-type="bibr" rid="pgen.1001016-Wang1">[33]</xref>. The <italic>TERT</italic> promoter contains numerous MYC binding sites that mediate <italic>TERT</italic> transcriptional activation <xref ref-type="bibr" rid="pgen.1001016-Wu1">[34]</xref>, suggesting that <italic>TERT</italic> is a target of MYC activity. Although <italic>TERT</italic> variants have not been previously reported to be associated with ovarian cancer, multiple genome-wide association studies have reported associations with this locus and risk of other cancers. Further analyses of this locus, including fine mapping, resequencing and functional assays, will be necessary to definitively identify the causal SNP(s).</p>
</sec><sec id="s4" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Study populations</title>
<p>Approval from respective human research ethics committees was obtained, and all participants provided written informed consent. Sixteen OCAC case-control studies (summarized in <xref ref-type="supplementary-material" rid="pgen.1001016.s003">Table S2</xref>) contributed data to this two-stage risk analysis. Samples in the discovery stage were derived from two case-control studies, AUS (550 cases and 1,101 controls) and MAY (125 cases and 61 controls). Cases in the discovery set were all diagnosed with serous carcinoma of the ovary, fallopian tube or peritoneum, and most of the participants were non-Hispanic white women. Cases and controls from an additional 14 OCAC studies, as well as an additional 284 AUS and 477 MAY samples, including cases with other histologies, were included in a stage 2 analysis designed to replicate the most promising SNPs from the discovery stage. Fifteen studies used population-based case and control ascertainment, and one (MAY) was clinic-based. All studies have been previously described <xref ref-type="bibr" rid="pgen.1001016-Song1">[7]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Pearce1">[35]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Ramus1">[36]</xref>. The final combined dataset of all discovery and replication samples consisted of a total of 10,067 controls (9,953 were self-classified as non-Hispanic White) and 5,976 ovarian cancer cases of all histologies and morphologies, including 3,734 serous invasive cases (3,710 were self-classified as non-Hispanic Whites) (<xref ref-type="supplementary-material" rid="pgen.1001016.s003">Table S2</xref>).</p>
</sec><sec id="s4b">
<title>Candidate gene and SNP selection</title>
<p>Our approach and our choice of candidate genes was based on extensive preliminary data we have accumulated from gene expression profiles of co-cultured of theca fibroblast and epithelial ovarian cells (I. Haviv, personal communication), and expression profiles of murine ovarian epithelial cells identifying candidates that are regulated through the estrus cycle <xref ref-type="bibr" rid="pgen.1001016-Gava1">[37]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Spentzos1">[38]</xref> (see <xref ref-type="supplementary-material" rid="pgen.1001016.s006">Text S1</xref>). A compiled list of candidates was uploaded on the Ingenuity Pathway Analysis web interface and GeneSpring GX in order to obtain further candidates inferred from the literature. Prioritisation based on literature evidence for a plausible role in oncogenesis resulted in a list of 255 candidate genes of interest including <italic>CXCL9</italic>, <italic>CTGF</italic>, <italic>LCN2</italic>, <italic>DCN</italic>, and <italic>VIL2</italic>. CXCL9 is associated with ovarian cancer survival and acts by recruiting T-cells and inducing immune surveillance <xref ref-type="bibr" rid="pgen.1001016-Zhang1">[39]</xref>, and is expressed in epithelial cells co-cultured with fibroblasts. CTGF is likely to be the driver of the CAF phenotype. CTGF (TGFβ-stimulated) expression is associated with desmoplastic stroma <xref ref-type="bibr" rid="pgen.1001016-Frazier1">[40]</xref> and elevated angiogenesis <xref ref-type="bibr" rid="pgen.1001016-Yang1">[41]</xref>. <italic>LCN2</italic>, <italic>DCN</italic> and <italic>VIL2</italic> were regulated through the murine estrus cycle, and appear to be hormone responsive (either directly or indirectly) <xref ref-type="bibr" rid="pgen.1001016-Gava1">[37]</xref>. Furthermore, comparison with expression profiles of human ovarian carcinomas <xref ref-type="bibr" rid="pgen.1001016-Bonome1">[42]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Donninger1">[43]</xref> showed that all three are differentially expressed in tumors compared with normal epithelial cells. Further details for candidate gene selection and justification are provided in <xref ref-type="supplementary-material" rid="pgen.1001016.s006">Text S1</xref> and <xref ref-type="supplementary-material" rid="pgen.1001016.s002">Table S1</xref>.</p>
<p>We identified SNPs within 5 kb of these 255 genes (58,114 SNPs in total from dbSNP, Ensembl, the International HapMap Consortium <xref ref-type="bibr" rid="pgen.1001016-1">[44]</xref>, Perlegen Sciences <xref ref-type="bibr" rid="pgen.1001016-Hinds1">[45]</xref>, SeattleSNPs [pga.mbt.washington.edu/], NIEHS SNPs [<ext-link ext-link-type="uri" xlink:href="http://egp.gs.washington.edu" xlink:type="simple">http://egp.gs.washington.edu</ext-link>], and the Innate Immunity PGA [<ext-link ext-link-type="uri" xlink:href="http://www.nhlbi.nih.gov/resources/pga/" xlink:type="simple">http://www.nhlbi.nih.gov/resources/pga/</ext-link>]. We used the binning algorithm of ldSelect <xref ref-type="bibr" rid="pgen.1001016-Carlson1">[46]</xref> to identify 4,567 tagSNPs among these (r<sup>2</sup>&gt;0.8) and minor allele frequencies (MAFs)&gt;0.05 based on the most informative available source (84% of genes used HapMap, 10% used SeattleSNPs, 3% used Perlegen Sciences, 2% used NIEHS SNPs, and 1% used Innate Immunity PGA). We prioritized the list to 166 genes based on known function and the number of bins in each gene (excluding genes with a large number of bins), in an attempt to identify ∼1,500 key SNPs. Based on Illumina design scores, we picked the best tagSNP in each bin (or two tagSNPs, if there were &gt;10 tagSNPs in a bin but none of them had an optimal design score). We also used PATROCLES (<ext-link ext-link-type="uri" xlink:href="http://www.patrocles.org," xlink:type="simple">www.patrocles.org,</ext-link>) to identify supplemental SNPs with MAFs&gt;0.05 in microRNA binding sites or non-synonymous SNPs from public databases to the potential SNP list. This identified an additional 170 miRNA binding site SNPs and nsSNPs with Illumina design scores&gt;0.6. In total this gave 1,410 tagSNPs, miRNA binding site SNPs and nsSNPs. In order to reach the final total of 1,536 SNPs for the Illumina GoldenGate assay, we added tagSNPs in another 12 candidate genes with MAF≥0.01. The final list of 1,536 SNPs included 106 supplemental SNPs and 1,430 tagSNPs in 173 genes (see <xref ref-type="supplementary-material" rid="pgen.1001016.s002">Table S1</xref>).</p>
</sec><sec id="s4c">
<title>Genotyping and quality control</title>
<p>The discovery samples were predominantly non-Hispanic White women with serous ovarian cancer and controls derived from two studies, the AUS and MAY studies, and were genotyped using the Illumina GoldenGate assay and Illumina BeadStudio software <xref ref-type="bibr" rid="pgen.1001016-Fan1">[47]</xref>, <xref ref-type="bibr" rid="pgen.1001016-Oliphant1">[48]</xref>. Plates were prepared containing randomly mixed cases and controls, with two duplicated samples and one blank per plate (n = 20). The Illumina GoldenGate assay was performed according to the manufacturer's instructions. Following completion of the assay, all plates were analysed using Illumina BeadStudio software version 3.1.0.0. The original raw genotype dataset contained genotype information for 1,920 samples (including blanks and duplicates) and 1,536 SNPs. Following automatic clustering, SNPs were ranked using their GenTrain score (ranging from 0 to 1) and those with GenTrain scores&lt;0.5 were manually checked and adjusted according to Illumina guidelines. Samples with call rates below 95% and SNPs with call rates below 98% were excluded. A total of 1,292 SNPs passed this initial quality control (QC). Genotyping quality was also assessed using tests for Hardy-Weinberg equilibrium (HWE). Plots were examined for SNPs with significant deviations from HWE in controls (0.001&lt;<italic>P</italic>&lt;0.05) and the genotype data was excluded if the clustering was found to be suboptimal. SNPs with <italic>P</italic><sub>HWE</sub>&lt;0.001 were excluded from analysis. In addition, we genotyped 17 SNPs in <italic>CXCL9</italic>, <italic>CTGF</italic>, <italic>LCN2</italic>, <italic>DCN</italic>, and <italic>VIL2</italic>, that had not been amenable to the Illumina GoldenGate assay or failed QC criteria, at the Queensland Institute of Medical Research using MALDI-TOF mass spectrophotometric mass determination of allele-specific primer extension products with Sequenom's MassARRAY platform and iPLEX Gold technology. The final discovery dataset for analysis consisted of 675 cases and 1,162 controls with genotype data on 1,309 SNPs.</p>
<p>The three SNPs in <italic>PODXL</italic>, <italic>ITGA6</italic> and <italic>MMP3</italic> selected for replication by all participating OCAC sites (with the exception of <italic>MMP3</italic> at the MAY site) were genotyped with the TaqMan allele discrimination assay (Taqman Applied Biosystems, Foster City, CA), using primers designed by Assays-by-Design (Applied Biosystems). MAY genotyping of <italic>MMP3</italic> rs522616 was performed as part of a 1,536 Illumina Golden Gate Assay at the Mayo Clinic with cases and controls randomly mixed within each plate. Additional genotyping details are provided elsewhere <xref ref-type="bibr" rid="pgen.1001016-Cunningham1">[49]</xref>.</p>
<p>Samples from five OCAC case-control studies (MAL, SEA, UKO, USC and additional samples from AUS) were genotyped for these and other replication SNPs, at the Queensland Institute of Medical Research using Sequenom iPLEX Gold technology. Primer design was carried out according Sequenom's guidelines using MassARRAY Assay Design software (version 1.0). Multiplex PCR amplification of fragments containing target SNPs was performed using Qiagen HotStart Taq Polymerase and a Perkin Elmer GeneAmp 2400 thermal cycler with 10 ng genomic DNA in 384 well plates. Shrimp Alkaline Phosphatase and allele-specific primer extension reactions were carried out according to manufacturer's instructions for iPLEX GOLD chemistry. Assay data were analysed using Sequenom TYPER software (Version 3.4).</p>
<p>Only replication SNPs that met OCAC's QC criteria (including &gt;95% call rate, and &gt;98% concordance between duplicates) were included in the analysis <xref ref-type="bibr" rid="pgen.1001016-Song2">[50]</xref>.</p>
</sec><sec id="s4d">
<title>Statistical analysis</title>
<p>The primary test for association in stage 1 was univariate analyses of the relationship between SNP genotypes and risk of serous ovarian cancer using the PLINK v0.99 Whole Genome Association Analysis toolset (<ext-link ext-link-type="uri" xlink:href="http://pngu.mgh.harvard.edu/purcell/plink/" xlink:type="simple">http://pngu.mgh.harvard.edu/purcell/plink/</ext-link>) <xref ref-type="bibr" rid="pgen.1001016-Purcell1">[51]</xref>. Single-marker basic allelic association (χ<sup>2</sup> 1df) tests (–<italic>assoc</italic> option) analyses were performed on each of the 1,309 post-QC SNPs in a total of 1,837 women. PLINK default thresholds were utilized, resulting in further exclusions: maximum missing genotypes per person≤0.10 (–<italic>mind</italic> option), maximum failed genotypes per SNP≤0.10 (–<italic>geno</italic> option), MAF≥0.01 (–<italic>maf</italic> option). Summary statistics were obtained for each SNP on the frequency of missing genotype data among cases and controls as well as a comparison of ‘missingness’ between cases and controls using the Fisher's exact test (–<italic>test-missing</italic> option). Deviations from expected HWE proportions were analysed using the Fisher's exact test and the MAFs were also estimated for all SNPs. The Cochran Armitage Trend test (χ<sup>2</sup> 1df) assuming the log additive model (–<italic>model</italic> option) was performed to test the association between the minor allele of each SNP and serous ovarian tumors.</p>
<p>Selection of stage 1 SNPs for replication analyses in stage 2 was prioritized as follows: first, SNPs with at least one failed duplicate, SNPs with a significantly different proportion of missing genotype data between cases and controls (<italic>P</italic><sub>Miss</sub>&lt;0.05), SNPs not conforming to HWE criteria (see Genotyping and quality control) for either cases, controls or both, and SNPs with no significant trend in allelic dose response (<italic>P</italic><sub>Trend</sub>&gt;0.05) were excluded; secondly, we estimated from the remaining SNPs which were likely to be the best predictors of serous ovarian cancer risk by calculating the positive predictive value (PPV) using the <italic>P</italic><sub>Trend</sub> values, the power of the study to detect this association, and the prior probability of 0.0001 <xref ref-type="bibr" rid="pgen.1001016-Wacholder1">[52]</xref>. Cases and controls from up to 14 additional studies participating in OCAC were included in replication analyses. We selected the three SNPs with the highest PPV for the larger replication analysis by all studies. Some additional individuals from AUS and MAY (not in the discovery set) were included in the replication analysis. Replication samples were examined to determine the distribution of race/ethnicity across studies, and analyses were restricted to White non-Hispanic women with serous invasive ovarian tumors. Significant differences by study site between age at interview for controls and age and diagnosis for cases were assessed using the Student's <italic>t</italic>-test for comparison of means. The MAF for each SNP was estimated from the control population for each study. The combined odds ratios (OR) and their 95% confidence intervals (95% CIs) were obtained from unconditional logistic regression models for each SNP genotype. Assuming a log additive model of inheritance, the per-allele ORs and their 95% CIs associated with serous invasive ovarian cancer in non-Hispanic Whites for each SNP selected for replication were estimated by fitting the number of rare alleles carried as a continuous covariate. Separate comparisons for women with one copy (heterozygotes) and women with two copies (rare homozygotes) of the minor allele vs. those with no copies (reference homozygotes) were conducted for all replication SNPs. Between-study heterogeneity was assessed using the likelihood ratio test to compare logistic regression models with and without a genotype-by-study interaction term. Risk estimates from all replication analyses were adjusted for age at diagnosis for cases or age at interview for controls and study site. Exploratory analyses combining all ethnicities were additionally adjusted for ethnicity. Forest plots generated in exploratory analyses according to histological subtype were obtained using the <italic>rmeta</italic> library (v2.15) implemented in the R project for Statistical Computing (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/" xlink:type="simple">http://www.r-project.org/</ext-link>), and LD plots were generated using Haploview v4.1 <xref ref-type="bibr" rid="pgen.1001016-Barrett1">[53]</xref>. All tests for association were two-tailed, and unless otherwise specified, statistical significance was assessed at <italic>p</italic>&lt;0.05 and tests for association in stage 2 were performed in STATA v. 9.0 (StataCorp, USA).</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pgen.1001016.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.s001" xlink:type="simple"><label>Figure S1</label><caption>
<p>Study design for two-stage analysis of selected SNPs in genes involved in stromal-epithelial interactions in the Ovarian Cancer Association Consortium (OCAC).</p>
<p>(0.08 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="pgen.1001016.s002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.s002" xlink:type="simple"><label>Table S1</label><caption>
<p>Candidate genes, putative role/special justification for selection and reference list.</p>
<p>(0.05 MB DOC)</p>
</caption></supplementary-material><supplementary-material id="pgen.1001016.s003" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.s003" xlink:type="simple"><label>Table S2</label><caption>
<p>Characteristics of serous ovarian cancer cases and controls used in discovery and replication analyses according to contributing OCAC study.</p>
<p>(0.05 MB DOC)</p>
</caption></supplementary-material><supplementary-material id="pgen.1001016.s004" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.s004" xlink:type="simple"><label>Table S3</label><caption>
<p>SNPs successfully genotyped (Illumina &amp; Sequenom) in the discovery stage with P<sub>Trend</sub>≤0.05 for serous ovarian cancer risk.</p>
<p>(0.12 MB DOC)</p>
</caption></supplementary-material><supplementary-material id="pgen.1001016.s005" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.s005" xlink:type="simple"><label>Table S4</label><caption>
<p>Study heterogeneity <italic>p</italic>-values for serous ovarian cancer risk estimates among non-Hispanic whites for SNPs reported in <xref ref-type="table" rid="pgen-1001016-t002">Table 2</xref>.</p>
<p>(0.04 MB DOC)</p>
</caption></supplementary-material><supplementary-material id="pgen.1001016.s006" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pgen.1001016.s006" xlink:type="simple"><label>Text S1</label><caption>
<p>Candidate gene selection and justification.</p>
<p>(0.06 MB DOC)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of OCAC through their donations to the Ovarian Cancer Research Fund. The PBCS thanks Dr. Louise Brinton and Mark Sherman from the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, USA, Drs. Neonila Szeszenia-Dabrowska and Beata Peplonska of the Nofer Institute of Occupational Medicine (Lodz, Poland), Witold Zatonski of the Department of Cancer Epidemiology and Prevention, The M. Sklodowska-Curie Cancer Center and Institute of Oncology (Warsaw, Poland), and Pei Chao and Michael Stagner from Information Management Services (Sliver Spring MD, USA), for their valuable contributions to the study. The GER study acknowledges Ursula Eilber and Tanja Koehler for competent technical assistance for German Ovarian Cancer study. The AOCS Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see <ext-link ext-link-type="uri" xlink:href="http://www.aocstudy.org/" xlink:type="simple">http://www.aocstudy.org/</ext-link>). The AOCS and ACS Management Group (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) thank all of the project staff and collaborating institutions. We also thank all the participants in all the participating studies.</p>
<p><bold>The Ovarian Cancer Association Consortium</bold></p>
<p>Georgia Chenevix-Trench, Sharon E. Johnatty, Jonathan Beesley, Xiaoqing Chen, Penelope M. Webb, The Australian Cancer Study (Ovarian Cancer), The Australian Ovarian Cancer Study Group, The Queensland Institute of Medical Research, Queensland; Peter MacCallum Cancer Centre, Melbourne Victoria (AUSTRALIA); Anna H. Wu, Malcolm C. Pike, Celeste Leigh Pearce, Christopher K. Edlund, David J. Van Den Berg, University of Southern California, Keck School of Medicine, Los Angeles, CA; Montserrat Garcia-Closas, Hannah P. Yang, Stephen Chanock, Nicolas Wentzensen, Louise A. Brinton, National Cancer Institute, National Institutes of Health, Rockville, MD; Hoda Anton-Culver , Argyrios Ziogas, Wendy Brewster, School of Medicine, University of California, Irvine, CA; Ellen L. Goode, Brooke L. Fridley, Robert A. Vierkant, Julie M. Cunningham, Mayo Clinic College of Medicine, Rochester, MN; Andrew Berchuck, Joellen M. Schildkraut, Edwin S. Iversen, Jr, Patricia G. Moorman, Duke University Medical Center, Durham, NC; Marc T. Goodman, Michael E. Carney, Pamela J. Thompson, Galina Lurie, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI; Daniel W. Cramer, Margaret A. Gates, Immaculata DeVivo, Susan E. Hankinson, Shelley S. Tworoger, Kathryn L. Terry, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA; Jennifer A. Doherty, Kara L. Cushing-Haugen, Chu Chen, Mary Anne Rossing, Fred Hutchinson Cancer Research Center, Seattle,WA; Linda S. Cook, Department of Internal Medicine, University of New Mexico. Albuquerque, NM; Kirsten Moysich, Richard DiCioccio, Matthew T. Grasela, Roswell Park Cancer Institute, Buffalo, NY; Roberta B. Ness, University of Texas School of Public Health, Houston, TX; Alice S. Whittemore, Valerie McGuire, Weiva Sieh, Stanford University School of Medicine, Stanford, CA; Johnathan M. Lancaster, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL; Rachel T. Palmieri,University of North Carolina at Chapel Hill, NC; Harvey A. Risch, Yale University School of Public Health, New Haven, CT (UNITED STATES); Claus Hogdall, Estrid Hogdall, Susanne Krüger Kjaer, Danish Cancer Society/The Juliane Marie Centre, Copenhagen (DENMARK); Ralf Bützow, University of Helsinki, Haartman Insitute, Helsinki (FINLAND); Simon A. Gayther , Aleksandra Gentry-Maharaj, Usha Menon, Susan J. Ramus, University College London, London, Paul D.P. Pharoah, Barbara Perkins, Mitul Shah, Honglin Song, University of Cambridge, Strangeways Research Laboratory, Cambridge (UNITED KINGDOM), Linda E Kelemen, Alberta Health Services, Calgary (CANADA), Jacek Gronwald, Jan Lubinski, Pomeranian Medical University, Szczecin; Jolanta Lissowska, Cancer Center and M Sklodowska-Curie Institute of Oncology, Warszawa (POLAND); Jenny Chang-Claude, Deutsches Krebsforschungszentrum, Heidelberg; Shan Wang-Gohrke, University of Ulm, Ulm (GERMANY).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pgen.1001016-Parkin1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Bray</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Pisani</surname><given-names>P</given-names></name>
</person-group>             <year>2005</year>             <article-title>Global cancer statistics, 2002.</article-title>             <source>CA Cancer J Clin</source>             <volume>55</volume>             <fpage>74</fpage>             <lpage>108</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Wenham1"><label>2</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wenham</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Lancaster</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Berchuck</surname><given-names>A</given-names></name>
</person-group>             <year>2002</year>             <article-title>Molecular aspects of ovarian cancer.</article-title>             <source>Best Pract Res Clin Obstet Gynaecol</source>             <volume>16</volume>             <fpage>483</fpage>             <lpage>497</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Whittemore1"><label>3</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Whittemore</surname><given-names>AS</given-names></name>
</person-group>             <year>1994</year>             <article-title>Characteristics relating to ovarian cancer risk: implications for prevention and detection.</article-title>             <source>Gynecol Oncol</source>             <volume>55</volume>             <fpage>S15</fpage>             <lpage>19</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Pharoah1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pharoah</surname><given-names>PD</given-names></name>
<name name-style="western"><surname>Ponder</surname><given-names>BA</given-names></name>
</person-group>             <year>2002</year>             <article-title>The genetics of ovarian cancer.</article-title>             <source>Best Pract Res Clin Obstet Gynaecol</source>             <volume>16</volume>             <fpage>449</fpage>             <lpage>468</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Boyd1"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Boyd</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Rubin</surname><given-names>SC</given-names></name>
</person-group>             <year>1997</year>             <article-title>Hereditary ovarian cancer: molecular genetics and clinical implications.</article-title>             <source>Gynecol Oncol</source>             <volume>64</volume>             <fpage>196</fpage>             <lpage>206</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Gayther1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gayther</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Ramus</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Kjaer</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Whittemore</surname><given-names>AS</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.</article-title>             <source>Cancer Res</source>             <volume>67</volume>             <fpage>3027</fpage>             <lpage>3035</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Song1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Song</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Ramus</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Tyrer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Bolton</surname><given-names>KL</given-names></name>
<name name-style="western"><surname>Gentry-Maharaj</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>996</fpage>             <lpage>1000</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Risch1"><label>8</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Risch</surname><given-names>HA</given-names></name>
</person-group>             <year>1998</year>             <article-title>Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.</article-title>             <source>J Natl Cancer Inst</source>             <volume>90</volume>             <fpage>1774</fpage>             <lpage>1786</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Riman1"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Riman</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Persson</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Nilsson</surname><given-names>S</given-names></name>
</person-group>             <year>1998</year>             <article-title>Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence.</article-title>             <source>Clin Endocrinol (Oxf)</source>             <volume>49</volume>             <fpage>695</fpage>             <lpage>707</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Fathalla1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Fathalla</surname><given-names>MF</given-names></name>
</person-group>             <year>1971</year>             <article-title>Incessant ovulation–a factor in ovarian neoplasia?</article-title>             <source>Lancet</source>             <volume>2</volume>             <fpage>163</fpage>          </element-citation></ref>
<ref id="pgen.1001016-Fleming1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Fleming</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Beaugie</surname><given-names>CR</given-names></name>
<name name-style="western"><surname>Haviv</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Chenevix-Trench</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Tan</surname><given-names>OL</given-names></name>
</person-group>             <year>2006</year>             <article-title>Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.</article-title>             <source>Mol Cell Endocrinol</source>             <volume>247</volume>             <fpage>4</fpage>             <lpage>21</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Cunha1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cunha</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Hayward</surname><given-names>SW</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>YZ</given-names></name>
<name name-style="western"><surname>Ricke</surname><given-names>WA</given-names></name>
</person-group>             <year>2003</year>             <article-title>Role of the stromal microenvironment in carcinogenesis of the prostate.</article-title>             <source>Int J Cancer</source>             <volume>107</volume>             <fpage>1</fpage>             <lpage>10</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Jacks1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jacks</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></name>
</person-group>             <year>2002</year>             <article-title>Taking the study of cancer cell survival to a new dimension.</article-title>             <source>Cell</source>             <volume>111</volume>             <fpage>923</fpage>             <lpage>925</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Sadlonova1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sadlonova</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Novak</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>MR</given-names></name>
<name name-style="western"><surname>Bowe</surname><given-names>DB</given-names></name>
<name name-style="western"><surname>Gault</surname><given-names>SR</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture.</article-title>             <source>Breast Cancer Res</source>             <volume>7</volume>             <fpage>R46</fpage>             <lpage>59</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Orimo1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Orimo</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></name>
</person-group>             <year>2006</year>             <article-title>Stromal fibroblasts in cancer: a novel tumor-promoting cell type.</article-title>             <source>Cell Cycle</source>             <volume>5</volume>             <fpage>1597</fpage>             <lpage>1601</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Tothill1"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tothill</surname><given-names>RW</given-names></name>
<name name-style="western"><surname>Tinker</surname><given-names>AV</given-names></name>
<name name-style="western"><surname>George</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Fox</surname><given-names>SB</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.</article-title>             <source>Clin Cancer Res</source>             <volume>14</volume>             <fpage>5198</fpage>             <lpage>5208</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Johnatty1"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Johnatty</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Beesley</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Spurdle</surname><given-names>AB</given-names></name>
<name name-style="western"><surname>Defazio</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.</article-title>             <source>Twin Res Hum Genet</source>             <volume>12</volume>             <fpage>269</fpage>             <lpage>275</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Skol1"><label>18</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Skol</surname><given-names>AD</given-names></name>
<name name-style="western"><surname>Scott</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Abecasis</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Boehnke</surname><given-names>M</given-names></name>
</person-group>             <year>2006</year>             <article-title>Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies.</article-title>             <source>Nat Genet</source>             <volume>38</volume>             <fpage>209</fpage>             <lpage>213</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Campisi1"><label>19</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Campisi</surname><given-names>J</given-names></name>
</person-group>             <year>2005</year>             <article-title>Suppressing cancer: the importance of being senescent.</article-title>             <source>Science</source>             <volume>309</volume>             <fpage>886</fpage>             <lpage>887</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Feldser1"><label>20</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Feldser</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Hackett</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Greider</surname><given-names>CW</given-names></name>
</person-group>             <year>2003</year>             <article-title>Telomere dysfunction and the initiation of genome instability.</article-title>             <source>Nat Rev Cancer</source>             <volume>3</volume>             <fpage>623</fpage>             <lpage>627</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Shete1"><label>21</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Shete</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hosking</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Robertson</surname><given-names>LB</given-names></name>
<name name-style="western"><surname>Dobbins</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Sanson</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Genome-wide association study identifies five susceptibility loci for glioma.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>899</fpage>             <lpage>904</lpage>          </element-citation></ref>
<ref id="pgen.1001016-McKay1"><label>22</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>McKay</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Hung</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Gaborieau</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Boffetta</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Chabrier</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Lung cancer susceptibility locus at 5p15.33.</article-title>             <source>Nat Genet</source>             <volume>40</volume>             <fpage>1404</fpage>             <lpage>1406</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Landi1"><label>23</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Landi</surname><given-names>MT</given-names></name>
<name name-style="western"><surname>Chatterjee</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Goldin</surname><given-names>LR</given-names></name>
<name name-style="western"><surname>Goldstein</surname><given-names>AM</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma.</article-title>             <source>Am J Hum Genet</source>             <volume>85</volume>             <fpage>679</fpage>             <lpage>691</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Stacey1"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Stacey</surname><given-names>SN</given-names></name>
<name name-style="western"><surname>Sulem</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Masson</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Gudjonsson</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Thorleifsson</surname><given-names>G</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>New common variants affecting susceptibility to basal cell carcinoma.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>909</fpage>             <lpage>914</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Petersen1"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Petersen</surname><given-names>GM</given-names></name>
<name name-style="western"><surname>Amundadottir</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Fuchs</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Kraft</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Stolzenberg-Solomon</surname><given-names>RZ</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.</article-title>             <source>Nat Genet (provisional acceptance)</source>          </element-citation></ref>
<ref id="pgen.1001016-Rafnar1"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rafnar</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Sulem</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Stacey</surname><given-names>SN</given-names></name>
<name name-style="western"><surname>Geller</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Gudmundsson</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>221</fpage>             <lpage>227</lpage>          </element-citation></ref>
<ref id="pgen.1001016-deBakker1"><label>27</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>de Bakker</surname><given-names>PI</given-names></name>
<name name-style="western"><surname>Yelensky</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Pe'er</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Gabriel</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>MJ</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Efficiency and power in genetic association studies.</article-title>             <source>Nat Genet</source>             <volume>37</volume>             <fpage>1217</fpage>             <lpage>1223</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Amankwah1"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Amankwah</surname><given-names>EK</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Tsai</surname><given-names>Y-Y</given-names></name>
<name name-style="western"><surname>Fridley</surname><given-names>BL</given-names></name>
<name name-style="western"><surname>Beesley</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Single nucleotide polymorphisms in stromal genes decorin and lumican and susceptibility to serous ovarian cancer in three study populations.</article-title>             <source>Cancer Res (provisional acceptance)</source>          </element-citation></ref>
<ref id="pgen.1001016-Easton1"><label>29</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Easton</surname><given-names>DF</given-names></name>
<name name-style="western"><surname>Pooley</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Dunning</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Pharoah</surname><given-names>PD</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Genome-wide association study identifies novel breast cancer susceptibility loci.</article-title>             <source>Nature</source>             <volume>447</volume>             <fpage>1087</fpage>             <lpage>1093</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Gudmundsson1"><label>30</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gudmundsson</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Sulem</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Gudbjartsson</surname><given-names>DF</given-names></name>
<name name-style="western"><surname>Blondal</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Gylfason</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>1122</fpage>             <lpage>1126</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Tuupanen1"><label>31</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tuupanen</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Turunen</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Lehtonen</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Hallikas</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Vanharanta</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>885</fpage>             <lpage>890</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Pomerantz1"><label>32</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pomerantz</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Ahmadiyeh</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Jia</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Herman</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Verzi</surname><given-names>MP</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>882</fpage>             <lpage>884</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Wang1"><label>33</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>LY</given-names></name>
<name name-style="western"><surname>Allan</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Beach</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hannon</surname><given-names>GJ</given-names></name>
</person-group>             <year>1998</year>             <article-title>Myc activates telomerase.</article-title>             <source>Genes Dev</source>             <volume>12</volume>             <fpage>1769</fpage>             <lpage>1774</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Wu1"><label>34</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>KJ</given-names></name>
<name name-style="western"><surname>Grandori</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Amacker</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Simon-Vermot</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Polack</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Direct activation of TERT transcription by c-MYC.</article-title>             <source>Nat Genet</source>             <volume>21</volume>             <fpage>220</fpage>             <lpage>224</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Pearce1"><label>35</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pearce</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Near</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Van Den Berg</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Ramus</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Gentry-Maharaj</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.</article-title>             <source>Br J Cancer</source>             <volume>100</volume>             <fpage>412</fpage>             <lpage>420</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Ramus1"><label>36</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Ramus</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Vierkant</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Johnatty</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Pike</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Van Den Berg</surname><given-names>DJ</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Consortium analysis of 7 candidate SNPs for ovarian cancer.</article-title>             <source>Int J Cancer</source>             <volume>123</volume>             <fpage>380</fpage>             <lpage>388</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Gava1"><label>37</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gava</surname><given-names>N</given-names></name>
<name name-style="western"><surname>C</surname><given-names>LC</given-names></name>
<name name-style="western"><surname>Bye</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Byth</surname><given-names>K</given-names></name>
<name name-style="western"><surname>deFazio</surname><given-names>A</given-names></name>
</person-group>             <year>2008</year>             <article-title>Global gene expression profiles of ovarian surface epithelial cells in vivo.</article-title>             <source>J Mol Endocrinol</source>             <volume>40</volume>             <fpage>281</fpage>             <lpage>296</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Spentzos1"><label>38</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Spentzos</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Levine</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Ramoni</surname><given-names>MF</given-names></name>
<name name-style="western"><surname>Joseph</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>X</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>A Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer.</article-title>             <source>J Clin Oncol</source>             <fpage>JCO.2004.2004.2070</fpage>          </element-citation></ref>
<ref id="pgen.1001016-Zhang1"><label>39</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Conejo-Garcia</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Katsaros</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Gimotty</surname><given-names>PA</given-names></name>
<name name-style="western"><surname>Massobrio</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.</article-title>             <source>N Engl J Med</source>             <volume>348</volume>             <fpage>203</fpage>             <lpage>213</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Frazier1"><label>40</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Frazier</surname><given-names>KS</given-names></name>
<name name-style="western"><surname>Grotendorst</surname><given-names>GR</given-names></name>
</person-group>             <year>1997</year>             <article-title>Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors.</article-title>             <source>Int J Biochem Cell Biol</source>             <volume>29</volume>             <fpage>153</fpage>             <lpage>161</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Yang1"><label>41</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Tuxhorn</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Ressler</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>McAlhany</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Dang</surname><given-names>TD</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis.</article-title>             <source>Cancer Res</source>             <volume>65</volume>             <fpage>8887</fpage>             <lpage>8895</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Bonome1"><label>42</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bonome</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Radonovich</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pise-Masison</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.</article-title>             <source>Cancer Res</source>             <volume>65</volume>             <fpage>10602</fpage>             <lpage>10612</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Donninger1"><label>43</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Donninger</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Bonome</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Radonovich</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pise-Masison</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Brady</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.</article-title>             <source>Oncogene</source>             <volume>23</volume>             <fpage>8065</fpage>             <lpage>8077</lpage>          </element-citation></ref>
<ref id="pgen.1001016-1"><label>44</label><element-citation publication-type="journal" xlink:type="simple">             <year>2003</year>             <article-title>The International HapMap Project.</article-title>             <source>Nature</source>             <volume>426</volume>             <fpage>789</fpage>             <lpage>796</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Hinds1"><label>45</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hinds</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Stuve</surname><given-names>LL</given-names></name>
<name name-style="western"><surname>Nilsen</surname><given-names>GB</given-names></name>
<name name-style="western"><surname>Halperin</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Eskin</surname><given-names>E</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Whole-genome patterns of common DNA variation in three human populations.</article-title>             <source>Science</source>             <volume>307</volume>             <fpage>1072</fpage>             <lpage>1079</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Carlson1"><label>46</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Carlson</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Eberle</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Rieder</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Yi</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Kruglyak</surname><given-names>L</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.</article-title>             <source>Am J Hum Genet</source>             <volume>74</volume>             <fpage>106</fpage>             <lpage>120</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Fan1"><label>47</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Fan</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Craumer</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Barker</surname><given-names>D</given-names></name>
</person-group>             <year>2005</year>             <article-title>BeadArray-based solutions for enabling the promise of pharmacogenomics.</article-title>             <source>Biotechniques</source>             <volume>39</volume>             <fpage>S583</fpage>             <lpage>588</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Oliphant1"><label>48</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Oliphant</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Barker</surname><given-names>DL</given-names></name>
<name name-style="western"><surname>Stuelpnagel</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Chee</surname><given-names>MS</given-names></name>
</person-group>             <year>2002</year>             <article-title>BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping.</article-title>             <source>Biotechniques</source>             <volume>Suppl</volume>             <fpage>56</fpage>             <lpage>58, 60-51</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Cunningham1"><label>49</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cunningham</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Sellers</surname><given-names>TA</given-names></name>
<name name-style="western"><surname>Schildkraut</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Fredericksen</surname><given-names>ZS</given-names></name>
<name name-style="western"><surname>Vierkant</surname><given-names>RA</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Performance of amplified DNA in an Illumina GoldenGate BeadArray assay.</article-title>             <source>Cancer Epidemiol Biomarkers Prev</source>             <volume>17</volume>             <fpage>1781</fpage>             <lpage>1789</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Song2"><label>50</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Song</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Ramus</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Kjaer</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>DiCioccio</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Chenevix-Trench</surname><given-names>G</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.</article-title>             <source>Hum Mol Genet</source>             <volume>18</volume>             <fpage>2297</fpage>             <lpage>2304</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Purcell1"><label>51</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Purcell</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Neale</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Todd-Brown</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Ferreira</surname><given-names>MA</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses.</article-title>             <source>Am J Hum Genet</source>             <volume>81</volume>             <fpage>559</fpage>             <lpage>575</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Wacholder1"><label>52</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wacholder</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Chanock</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Garcia-Closas</surname><given-names>M</given-names></name>
<name name-style="western"><surname>El ghormli</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Rothman</surname><given-names>N</given-names></name>
</person-group>             <year>2004</year>             <article-title>Assessing the Probability That a Positive Report is False: An Approach for Molecular Epidemiology Studies.</article-title>             <source>J Natl Cancer Inst</source>             <volume>96</volume>             <fpage>434</fpage>             <lpage>442</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Barrett1"><label>53</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Barrett</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Fry</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Maller</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Daly</surname><given-names>MJ</given-names></name>
</person-group>             <year>2005</year>             <article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title>             <source>Bioinformatics</source>             <volume>21</volume>             <fpage>263</fpage>             <lpage>265</lpage>          </element-citation></ref>
<ref id="pgen.1001016-Gabriel1"><label>54</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Gabriel</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Schaffner</surname><given-names>SF</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Moore</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Roy</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2002</year>             <article-title>The structure of haplotype blocks in the human genome.</article-title>             <source>Science</source>             <volume>296</volume>             <fpage>2225</fpage>             <lpage>2229</lpage>          </element-citation></ref>
</ref-list>

</back>
</article>